gamma-aminobutyric acid has been researched along with Bipolar Disorder in 238 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Topiramate, a structurally novel anticonvulsant, is being evaluated for other neurological conditions such as migraine, neuropathic pain, and essential tremor, and also for psychiatric conditions such as bipolar disorder, bulimia, post-traumatic stress disorder, and schizoaffective disorder, in addition to obesity." | 10.19 | The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. ( Chengappa, KN; Gershon, S; Levine, J, 2001) |
| "The pharmacological profile of topiramate is compared to other established and putative mood stabilizers, and a rationale for its use in bipolar disorder is presented." | 10.19 | The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. ( Chengappa, KN; Gershon, S; Levine, J, 2001) |
| "Topiramate appears to show promise as an addition to the agents available to treat bipolar disorder." | 10.19 | The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. ( Chengappa, KN; Gershon, S; Levine, J, 2001) |
| "To conduct the first randomized, controlled trial assessing the prophylactic efficacy of gabapentin in bipolar disorder." | 9.12 | A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. ( Colom, F; Comes, M; Manuel Goikolea, J; Martínez-Arán, A; Masramon, X; Sanchez-Moreno, J; Verger, K; Vieta, E, 2006) |
| "This small, randomized clinical trial comparing the prophylactic efficacy of adjunctive gabapentin to placebo suggests that, despite lack of acute efficacy, treatment with gabapentin might provide some benefit on the long-term outcome of bipolar disorder." | 9.12 | A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. ( Colom, F; Comes, M; Manuel Goikolea, J; Martínez-Arán, A; Masramon, X; Sanchez-Moreno, J; Verger, K; Vieta, E, 2006) |
| "Prior work reported elevated gray matter (GM) lactate and Glx (glutamate + glutamine + GABA) concentrations in unmedicated patients with bipolar disorder (BP) compared with healthy controls (HC)." | 9.11 | Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. ( Dager, SR; Demopulos, C; Dunner, DL; Friedman, SD; Hirashima, F; Lyoo, IK; Parow, A; Renshaw, PF; Stoll, AL, 2004) |
| "[corrected] To assess efficacy and safety of gabapentin in the treatment of bipolar disorder." | 9.09 | Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. ( Crockatt, JG; Janney, CA; Pande, AC; Tsaroucha, G; Werth, JL, 2000) |
| "The findings of this study did not demonstrate that gabapentin is an effective adjunctive treatment when administered to outpatients with bipolar disorder." | 9.09 | Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. ( Crockatt, JG; Janney, CA; Pande, AC; Tsaroucha, G; Werth, JL, 2000) |
| "We will include all randomised controlled trials (RCTs) reported as double-blind and comparing gabapentin or pregabalin with placebo or any other active pharmacological treatment (any preparation, dose, frequency, route of delivery or setting) in patients with bipolar disorder, anxiety or insomnia." | 8.95 | Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. ( Atkinson, LZ; Awad, A; Cipriani, A; Forrest, A; Geddes, JR; Harrison, PJ; Houghton, KT; Stockton, S, 2017) |
| " Gabapentin and pregabalin, a very similar drug with the same mechanism of action, bind to a subunit of voltage-dependent calcium channels which are implicated in the aetiopathogenesis of bipolar disorder, anxiety and insomnia." | 8.95 | Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. ( Atkinson, LZ; Awad, A; Cipriani, A; Forrest, A; Geddes, JR; Harrison, PJ; Houghton, KT; Stockton, S, 2017) |
| " Controlled trials in elderly patients with epilepsy demonstrate efficacy and tolerability comparable to gabapentin." | 8.84 | Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. ( Nanry, K; Ramsay, E; Sajatovic, M; Thompson, T, 2007) |
| "Reports of lamotrigine therapy in elderly patients with epilepsy, bipolar disorder (BD), or dementia were identified by conducting an electronic search of major publication databases." | 8.84 | Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. ( Nanry, K; Ramsay, E; Sajatovic, M; Thompson, T, 2007) |
| "Review of the available literature suggests lamotrigine is effective and well tolerated in elderly patients with epilepsy and relatively well-tolerated and may be effective in delaying mood relapse, particularly in the depressive pole, in patients with BD." | 8.84 | Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. ( Nanry, K; Ramsay, E; Sajatovic, M; Thompson, T, 2007) |
| "[corrected] To review the effectiveness data on the use of gabapentin in bipolar disorders." | 8.81 | Gabapentin treatment for bipolar disorders. ( Maidment, ID, 2001) |
| " Key search terms included gabapentin, mood stabilizer, and bipolar disorder." | 8.81 | Gabapentin treatment for bipolar disorders. ( Maidment, ID, 2001) |
| "From the data presented, gabapentin cannot be recommended for treatment of bipolar disorder." | 8.81 | Gabapentin treatment for bipolar disorders. ( Maidment, ID, 2001) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 8.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| " Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders." | 8.80 | Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999) |
| "The utility of gabapentin and lamotrigine for the treatment of bipolar disorder is reviewed." | 8.80 | Gabapentin and lamotrigine in bipolar disorder. ( Botts, SR; Raskind, J, 1999) |
| "Low gamma-aminobutyric acid (GABA) is implicated in both anxiety and depression pathophysiology." | 7.80 | Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid. ( Boldrini, M; Cooper, TB; Currier, D; Ellis, SP; Malone, KM; Mann, JJ; Oquendo, MA; Sullivan, G; Watson, KT; Xie, S, 2014) |
| "Gamma-aminobutyric acid (GABA) abnormalities have been implicated in bipolar disorder." | 7.79 | Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder. ( Brady, RO; Cohen, BM; Cooper, AJ; Jensen, JE; McCarthy, JM; Ongür, D; Prescot, AP; Renshaw, PF, 2013) |
| " We evaluated a nationwide sample to determine whether the $430 million gabapentin off-label marketing lawsuit and accompanying media coverage affected gabapentin market share, substitution of other scientifically substantiated and unsubstantiated anticonvulsants, and anticonvulsant spending of Medicare/Medicaid patients diagnosed with bipolar disorder." | 7.78 | Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder. ( Chace, MJ; Fullerton, CA; Gilden, D; Huskamp, HA; Soumerai, SB; Zhang, F, 2012) |
| " The case of gabapentin use in bipolar disorder provides an opportunity to study the roles of marketing, clinical evidence, and prior authorization (PA) policy on off-label medication use." | 7.76 | The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion. ( Busch, AB; Frank, RG; Fullerton, CA, 2010) |
| "Chronic lamotrigine, which is effective in the depressive phase or rapid cycling bipolar disorder does not alter brain arachidonic acid turnover in the unanesthetized rat." | 7.74 | Chronic lamotrigine does not alter the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat: implications for the treatment of bipolar disorder. ( Bazinet, RP; Chang, L; Lee, HJ; Rao, JS; Rapoport, SI, 2007) |
| "Drugs that are effective in treating the manic phase of bipolar disorder (lithium, carbamazepine, and valproate) upon chronic administration to rats decrease the turnover of arachidonic acid in their brain phospholipids." | 7.74 | Chronic lamotrigine does not alter the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat: implications for the treatment of bipolar disorder. ( Bazinet, RP; Chang, L; Lee, HJ; Rao, JS; Rapoport, SI, 2007) |
| "We evaluated effectiveness and predictors of response of gabapentin (GBP) as adjunctive treatment in a sample of 43 subjects with DSM-III-R bipolar disorder who were resistant to standard mood stabilizers." | 7.71 | Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? ( Akiskal, HS; Frare, F; Moretti, L; Perugi, G; Ruffolo, G; Toni, C; Torti, C, 2002) |
| "The aim of the present study was to assess the efficacy of adjunctive gabapentin (GBP) in the treatment of patients with intellectual disability (ID) and bipolar spectrum disorders." | 7.71 | Adjunctive gabapentin in patients with intellectual disability and bipolar spectrum disorders. ( Carpiniello, B; Carta, MG; Dessì, I; Hardoy, MC; Hardoy, MJ, 2001) |
| "To determine if gabapentin is effective either as adjunctive treatment or as monotherapy for major affective disorders in a naturalistic setting." | 7.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "All charts of patients meeting DSM-IV criteria for bipolar disorder or unipolar major depressive disorder treated with gabapentin in a private psychiatric practice were reviewed and clinical response was assessed retrospectively using the Clinical Global Impressions scale for Improvement (CGI-I)." | 7.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "Gabapentin was moderately to markedly effective in 30% (15/50) of patients, with statistically nonsignificant differences between patients with bipolar disorder type I, bipolar disorder type II and NOS, and unipolar major depressive disorder." | 7.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "Gabapentin appears to be somewhat effective as add-on treatment in a subgroup of patients with mood disorders in a naturalistic setting." | 7.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "To evaluate the efficacy of gabapentin as an adjunctive treatment for bipolar disorder in both depressed and manic phases." | 7.70 | Gabapentin as an adjunctive treatment in bipolar disorder. ( Hasey, GM; Joffe, RT; MacQueen, GM; Marriott, M; Patelis Siotis, I; Robb, JC; Young, LT, 1999) |
| "These findings are consistent with others in establishing the efficacy of gabapentin in both phases of bipolar disorder." | 7.70 | Gabapentin as an adjunctive treatment in bipolar disorder. ( Hasey, GM; Joffe, RT; MacQueen, GM; Marriott, M; Patelis Siotis, I; Robb, JC; Young, LT, 1999) |
| "This report describes the results of maintenance treatment with gabapentin in 18 previously refractory Bipolar Disorder patients who initially responded to augmentation with gabapentin during the acute phase of their therapy." | 7.70 | Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment. ( Schaffer, CB; Schaffer, LC, 1999) |
| "Gabapentin was well tolerated by all patients, with the most common side-effect being sedation." | 6.69 | Gabapentin in the acute treatment of refractory bipolar disorder. ( Altshuler, LL; Brown, ES; Denicoff, K; Frye, M; Gitlin, M; Goodman, R; Hwang, S; Keck, PE; Kupka, R; Leverich, G; McElroy, SL; Nolen, W; Post, R; Suppes, T, 1999) |
| "Fourteen of the 18 (78%) treated for hypomania or mania had a positive response to a dosage range of 600-3,600 mg/day." | 6.69 | Gabapentin in the acute treatment of refractory bipolar disorder. ( Altshuler, LL; Brown, ES; Denicoff, K; Frye, M; Gitlin, M; Goodman, R; Hwang, S; Keck, PE; Kupka, R; Leverich, G; McElroy, SL; Nolen, W; Post, R; Suppes, T, 1999) |
| "Gabapentin has been extensively prescribed off-label for psychiatric indications, with little established evidence of efficacy." | 6.55 | Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. ( Atkinson, LZ; Awad, A; Cipriani, A; Forrest, A; Geddes, JR; Harrison, PJ; Houghton, KT; Stockton, S, 2017) |
| "Lamotrigine has positive effects on cognitive function, but occasionally produces insomnia." | 6.41 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| " A slow upward dose titration is recommended to reduce the incidence of serious rash, but this may delay the attainment of adequate dosage for 6 weeks." | 6.41 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders." | 6.40 | Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999) |
| " Lamotrigine may offer a much-needed treatment alternative for bipolar depression and could be found effective for acute mania, but the need for slow dosage adjustment and the risk of rash may limit overall clinical utility." | 6.40 | Gabapentin and lamotrigine in bipolar disorder. ( Botts, SR; Raskind, J, 1999) |
| " Open reports suggest usefulness of gabapentin as an adjunct in bipolar disorder, but double-blind trials failed to confirm efficacy in acute mania and treatment-resistant rapid-cycling bipolar disorder." | 6.20 | Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. ( Calabrese, JR; Kroeker, G; Kusumakar, V; Rao, R; Scarrow, G; Yatham, LN, 2002) |
| "Lamotrigine clearly fills an unmet need in treating bipolar depression and rapid-cycling bipolar disorder." | 6.20 | Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. ( Calabrese, JR; Kroeker, G; Kusumakar, V; Rao, R; Scarrow, G; Yatham, LN, 2002) |
| "Open studies and case observations have suggested that gabapentin may be effective in the treatment of bipolar disorder." | 6.19 | Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states. ( Akiskal, H; Perugi, G; Ruffolo, G; Sartini, S; Simonini, E; Toni, C, 1999) |
| "Topiramate, a structurally novel anticonvulsant, is being evaluated for other neurological conditions such as migraine, neuropathic pain, and essential tremor, and also for psychiatric conditions such as bipolar disorder, bulimia, post-traumatic stress disorder, and schizoaffective disorder, in addition to obesity." | 6.19 | The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. ( Chengappa, KN; Gershon, S; Levine, J, 2001) |
| "The pharmacological profile of topiramate is compared to other established and putative mood stabilizers, and a rationale for its use in bipolar disorder is presented." | 6.19 | The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. ( Chengappa, KN; Gershon, S; Levine, J, 2001) |
| "Topiramate appears to show promise as an addition to the agents available to treat bipolar disorder." | 6.19 | The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. ( Chengappa, KN; Gershon, S; Levine, J, 2001) |
| "Disrupted brain gamma-aminobutyric acid (GABA)/glutamate homeostasis is a promising target for pharmacological intervention in co-occurring bipolar disorder (BD) and cannabis use disorder (CUD)." | 5.51 | Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders. ( Arnold, L; Hix, S; Mellick, W; Prisciandaro, JJ; Squeglia, LM; Tolliver, BK, 2022) |
| "Drugs that are effective in treating the manic phase of bipolar disorder (lithium, carbamazepine, and valproate) upon chronic administration to rats decrease the turnover of arachidonic acid in their brain phospholipids." | 5.34 | Chronic lamotrigine does not alter the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat: implications for the treatment of bipolar disorder. ( Bazinet, RP; Chang, L; Lee, HJ; Rao, JS; Rapoport, SI, 2007) |
| " Mean dosage +/- SD at week 8 was 1270 +/- 561." | 5.31 | Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? ( Akiskal, HS; Frare, F; Moretti, L; Perugi, G; Ruffolo, G; Toni, C; Torti, C, 2002) |
| "Gabapentin is a relatively new anticonvulsant indicated for adjunctive therapy in the treatment of partial seizures, with and without secondary generalization, in adults with epilepsy." | 5.31 | Anorgasmia in a patient with bipolar disorder type 1 treated with gabapentin. ( Brannon, GE; Rolland, PD, 2000) |
| "Gabapentin is an anticonvulsant drug released in the United States in 1993 for use as adjunctive therapy in refractory partial epilepsy." | 5.31 | Gabapentin and methylphenidate treatment of a preadolescent with attention deficit hyperactivity disorder and bipolar disorder. ( Bailey, K; Hamrin, V, 2001) |
| "Gabapentin was moderately to markedly effective in 30% (15/50) of patients, with statistically nonsignificant differences between patients with bipolar disorder type I, bipolar disorder type II and NOS, and unipolar major depressive disorder." | 5.30 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "Symptoms consistent with bruxism are a common chief complaint in dental practice." | 5.30 | Antidepressant-induced bruxism successfully treated with gabapentin. ( Brown, ES; Hong, SC, 1999) |
| "A case of bruxism, anxiety, insomnia and tremor is reported in a man with bipolar disorder that developed a few days after he initiated venlafaxine therapy for depression." | 5.30 | Antidepressant-induced bruxism successfully treated with gabapentin. ( Brown, ES; Hong, SC, 1999) |
| "In this clinical trial, we studied the effects of adjunctive treatment with gabapentin in controlling the symptoms of acute mania in patients admitted with bipolar disorder." | 5.16 | Adjunctive treatment with gabapentin in bipolar patients during acute mania. ( Astaneh, AN; Rezaei, O, 2012) |
| "To conduct the first randomized, controlled trial assessing the prophylactic efficacy of gabapentin in bipolar disorder." | 5.12 | A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. ( Colom, F; Comes, M; Manuel Goikolea, J; Martínez-Arán, A; Masramon, X; Sanchez-Moreno, J; Verger, K; Vieta, E, 2006) |
| "This small, randomized clinical trial comparing the prophylactic efficacy of adjunctive gabapentin to placebo suggests that, despite lack of acute efficacy, treatment with gabapentin might provide some benefit on the long-term outcome of bipolar disorder." | 5.12 | A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. ( Colom, F; Comes, M; Manuel Goikolea, J; Martínez-Arán, A; Masramon, X; Sanchez-Moreno, J; Verger, K; Vieta, E, 2006) |
| "Prior work reported elevated gray matter (GM) lactate and Glx (glutamate + glutamine + GABA) concentrations in unmedicated patients with bipolar disorder (BP) compared with healthy controls (HC)." | 5.11 | Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. ( Dager, SR; Demopulos, C; Dunner, DL; Friedman, SD; Hirashima, F; Lyoo, IK; Parow, A; Renshaw, PF; Stoll, AL, 2004) |
| "Gabapentin (GBP) may be useful in bipolar disorders, including as adjunctive therapy for bipolar depression, although controlled studies suggest inefficacy as primary treatment for mania or treatment-resistant rapid cycling." | 5.10 | Gabapentin augmentation therapy in bipolar depression. ( Ketter, TA; Santosa, C; Schumacher, M; Strong, C; Wang, PW; Winsberg, ME, 2002) |
| "[corrected] To assess efficacy and safety of gabapentin in the treatment of bipolar disorder." | 5.09 | Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. ( Crockatt, JG; Janney, CA; Pande, AC; Tsaroucha, G; Werth, JL, 2000) |
| "The findings of this study did not demonstrate that gabapentin is an effective adjunctive treatment when administered to outpatients with bipolar disorder." | 5.09 | Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. ( Crockatt, JG; Janney, CA; Pande, AC; Tsaroucha, G; Werth, JL, 2000) |
| "Anticonvulsant agents such as carbamazepine and valproate are alternatives to lithium in treating subjects with bipolar disorder." | 5.09 | Topiramate as add-on treatment for patients with bipolar mania. ( Atzert, R; Brar, JS; Chengappa, KN; Delaney, J; Levin, H; Levine, J; Moffa, N; Parepally, H; Rathore, D; Solai, L, 1999) |
| "We will include all randomised controlled trials (RCTs) reported as double-blind and comparing gabapentin or pregabalin with placebo or any other active pharmacological treatment (any preparation, dose, frequency, route of delivery or setting) in patients with bipolar disorder, anxiety or insomnia." | 4.95 | Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. ( Atkinson, LZ; Awad, A; Cipriani, A; Forrest, A; Geddes, JR; Harrison, PJ; Houghton, KT; Stockton, S, 2017) |
| " Gabapentin and pregabalin, a very similar drug with the same mechanism of action, bind to a subunit of voltage-dependent calcium channels which are implicated in the aetiopathogenesis of bipolar disorder, anxiety and insomnia." | 4.95 | Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. ( Atkinson, LZ; Awad, A; Cipriani, A; Forrest, A; Geddes, JR; Harrison, PJ; Houghton, KT; Stockton, S, 2017) |
| " Despite the generally weak study design in the identified publications, the authors of the articles often commented on the promising nature of gabapentin therapy for bipolar disorder." | 4.84 | Gabapentin in the treatment of mental illness: the echo chamber of the case series. ( Carey, TS; Goodman, F; Melvin, CL; Morgan, LC; Oldham, JM; Ranney, LM; Whitener, L; Williams, JW, 2008) |
| " Controlled trials in elderly patients with epilepsy demonstrate efficacy and tolerability comparable to gabapentin." | 4.84 | Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. ( Nanry, K; Ramsay, E; Sajatovic, M; Thompson, T, 2007) |
| "Reports of lamotrigine therapy in elderly patients with epilepsy, bipolar disorder (BD), or dementia were identified by conducting an electronic search of major publication databases." | 4.84 | Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. ( Nanry, K; Ramsay, E; Sajatovic, M; Thompson, T, 2007) |
| "Review of the available literature suggests lamotrigine is effective and well tolerated in elderly patients with epilepsy and relatively well-tolerated and may be effective in delaying mood relapse, particularly in the depressive pole, in patients with BD." | 4.84 | Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. ( Nanry, K; Ramsay, E; Sajatovic, M; Thompson, T, 2007) |
| "The role of lithium carbonate in the maintenance treatment of bipolar disorder is well established." | 4.82 | Alternatives to lithium and divalproex in the maintenance treatment of bipolar disorder. ( Freeman, MP; Gelenberg, AJ; Gnanadesikan, M, 2003) |
| "[corrected] To review the effectiveness data on the use of gabapentin in bipolar disorders." | 4.81 | Gabapentin treatment for bipolar disorders. ( Maidment, ID, 2001) |
| " Key search terms included gabapentin, mood stabilizer, and bipolar disorder." | 4.81 | Gabapentin treatment for bipolar disorders. ( Maidment, ID, 2001) |
| "From the data presented, gabapentin cannot be recommended for treatment of bipolar disorder." | 4.81 | Gabapentin treatment for bipolar disorders. ( Maidment, ID, 2001) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 4.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| " Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders." | 4.80 | Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999) |
| "The utility of gabapentin and lamotrigine for the treatment of bipolar disorder is reviewed." | 4.80 | Gabapentin and lamotrigine in bipolar disorder. ( Botts, SR; Raskind, J, 1999) |
| "Considerable evidence implicates the neurotransmitter gamma-aminobutyric acid (GABA) in the biochemical pathophysiology of mood disorders." | 4.79 | GABA and mood disorders: a brief review and hypothesis. ( Petty, F, 1995) |
| " This protocol was validated by determining the postmortem cerebrospinal fluid (CSF) glutamic acid (Glu) and γ-aminobutyric acid (GABA) levels of 8 major depressive disorder (MDD) patients, 9 bipolar disorder (BD) patients, and 19 well-matched controls, while also testing the plasma and CSF AA levels of living MDD patients." | 3.83 | A sensitive and practical RP-HPLC-FLD for determination of the low neuroactive amino acid levels in body fluids and its application in depression. ( Bao, AM; Wu, JL; Wu, SH; Yu, SY, 2016) |
| "The down regulation of glutamic acid decarboxylase67 (GAD1), reelin (RELN), and BDNF expression in brain of schizophrenia (SZ) and bipolar (BP) disorder patients is associated with overexpression of DNA methyltransferase1 (DNMT1) and ten-eleven translocase methylcytosine dioxygenase1 (TET1)." | 3.81 | DNA-methyltransferase1 (DNMT1) binding to CpG rich GABAergic and BDNF promoters is increased in the brain of schizophrenia and bipolar disorder patients. ( Dong, E; Grayson, DR; Guidotti, A; Ruzicka, WB, 2015) |
| "Bipolar disorder (BD) has been consistently associated with abnormalities in the Glutamate/GABA-Glutamine cycle." | 3.81 | Anterior cingulate Glutamate-Glutamine cycle metabolites are altered in euthymic bipolar I disorder. ( da Costa Leite, C; Henning, A; Machado-Vieira, R; Moreno, RA; Otaduy, MC; Pastorello, BF; Soeiro-de-Souza, MG; Vallada, H, 2015) |
| "Low gamma-aminobutyric acid (GABA) is implicated in both anxiety and depression pathophysiology." | 3.80 | Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid. ( Boldrini, M; Cooper, TB; Currier, D; Ellis, SP; Malone, KM; Mann, JJ; Oquendo, MA; Sullivan, G; Watson, KT; Xie, S, 2014) |
| "Gamma-aminobutyric acid (GABA) abnormalities have been implicated in bipolar disorder." | 3.79 | Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder. ( Brady, RO; Cohen, BM; Cooper, AJ; Jensen, JE; McCarthy, JM; Ongür, D; Prescot, AP; Renshaw, PF, 2013) |
| "Gabapentin treatment was started at 300 mg/day and increased up to 2000 mg/day." | 3.79 | Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states. ( Akiskal, H; Perugi, G; Ruffolo, G; Sartini, S; Simonini, E; Toni, C, 1999) |
| "Lamotrigine was superior to placebo after 3 weeks as assessed by changes in the Montgomery-Asberg Depression Rating Scale (MADRS)." | 3.79 | Lamotrigine in the treatment of bipolar depression. ( Bowden, CL; Mitchell, P; Suppes, T, 1999) |
| " Slow dosage escalation yields good tolerability." | 3.79 | Lamotrigine in the treatment of bipolar depression. ( Bowden, CL; Mitchell, P; Suppes, T, 1999) |
| "We determined the gene expression of 32 markers of the pathways of the two main neurotransmitters of the PFC, gamma-aminobutyric acid (GABA) and l-glutamic acid (glutamate), by real-time quantitative PCR in human postmortem anterior cingulate cortex (ACC) and dorsolateral PFC (DLPFC) in elderly non-suicidal patients with major depressive disorder (MDD) or bipolar disorder (BD)." | 3.78 | Gene expression of GABA and glutamate pathway markers in the prefrontal cortex of non-suicidal elderly depressed patients. ( Bao, AM; Kamphuis, W; Lou, JS; Luchetti, S; Qi, XR; Swaab, DF; Zhao, J, 2012) |
| " We evaluated a nationwide sample to determine whether the $430 million gabapentin off-label marketing lawsuit and accompanying media coverage affected gabapentin market share, substitution of other scientifically substantiated and unsubstantiated anticonvulsants, and anticonvulsant spending of Medicare/Medicaid patients diagnosed with bipolar disorder." | 3.78 | Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder. ( Chace, MJ; Fullerton, CA; Gilden, D; Huskamp, HA; Soumerai, SB; Zhang, F, 2012) |
| " The case of gabapentin use in bipolar disorder provides an opportunity to study the roles of marketing, clinical evidence, and prior authorization (PA) policy on off-label medication use." | 3.76 | The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion. ( Busch, AB; Frank, RG; Fullerton, CA, 2010) |
| "We used magnetic resonance spectroscopy (MRS) to examine whole brain and regional GABA, glutamate and glutamine in 13 patients with bipolar disorder compared to a matched group of 11 healthy controls." | 3.75 | Brain GABA levels in patients with bipolar disorder. ( Jensen, JE; Kaufman, RE; Marks, EH; Ostacher, MJ; Pollack, MH; Renshaw, PF; Sachs, GS; Simon, NM, 2009) |
| "We examined reporting practices for trials of gabapentin funded by Pfizer and Warner-Lambert's subsidiary, Parke-Davis (hereafter referred to as Pfizer and Parke-Davis) for off-label indications (prophylaxis against migraine and treatment of bipolar disorders, neuropathic pain, and nociceptive pain), comparing internal company documents with published reports." | 3.75 | Outcome reporting in industry-sponsored trials of gabapentin for off-label use. ( Bero, L; Dickersin, K; Scherer, RW; Vedula, SS, 2009) |
| " One example is the pharmaceutical marketing to promote off-label use of gabapentin (Neurontin) for the treatment of bipolar disorder, the legality of which was later addressed in a major lawsuit by the National Association of Attorneys General." | 3.74 | Disseminating findings from a drug class review: using best practices to inform prescription of antiepileptic drugs for bipolar disorder. ( Carey, TS; Evans, WD; Kreps, G; Linden, T; Melvin, CL; Oldham, J; Ranney, LM, 2008) |
| "An [1H]-MRS was used to measure levels of GABA, of the combined concentration of Glu and glutamine (Gln), and of N-acetylaspartate (NAA) in occipital cortex in medication-free, fully recovered subjects with a history of recurrent unipolar depression (n = 15), bipolar disorder (n = 16), and a group of healthy controls (n = 18)." | 3.74 | Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. ( Ashworth, F; Bhagwagar, Z; Cowen, PJ; Evans, J; Jezzard, P; Matthews, PM; Sule, A; Wylezinska, M, 2007) |
| "Chronic lamotrigine, which is effective in the depressive phase or rapid cycling bipolar disorder does not alter brain arachidonic acid turnover in the unanesthetized rat." | 3.74 | Chronic lamotrigine does not alter the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat: implications for the treatment of bipolar disorder. ( Bazinet, RP; Chang, L; Lee, HJ; Rao, JS; Rapoport, SI, 2007) |
| "Drugs that are effective in treating the manic phase of bipolar disorder (lithium, carbamazepine, and valproate) upon chronic administration to rats decrease the turnover of arachidonic acid in their brain phospholipids." | 3.74 | Chronic lamotrigine does not alter the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat: implications for the treatment of bipolar disorder. ( Bazinet, RP; Chang, L; Lee, HJ; Rao, JS; Rapoport, SI, 2007) |
| "Postmortem CNS studies have suggested an uncoupling of the gamma-aminobutyric acid (GABA) and benzodiazepine binding sites on the hippocampal GABA(A) receptor in schizophrenia." | 3.73 | Changes in hippocampal GABAA receptor subunit composition in bipolar 1 disorder. ( Dean, B; McLeod, M; Scarr, E, 2005) |
| "Disturbances of gamma-aminobutyric acid interneurons in the cerebral cortex contribute to the pathophysiology of schizophrenia and bipolar disorder." | 3.72 | Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. ( Benes, FM; Walsh, JP; Woo, TU, 2004) |
| "To test the hypothesis that glutamatergic inputs onto gamma-aminobutyric acid interneurons via the N-methyl-d-aspartate (NMDA) receptor are altered in the anterior cingulate cortex in schizophrenia and bipolar disorder." | 3.72 | Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. ( Benes, FM; Walsh, JP; Woo, TU, 2004) |
| "The density of gamma-aminobutyric acid interneurons that express the NMDA NR(2A)subunit appears to be decreased in schizophrenia and bipolar disorder." | 3.72 | Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. ( Benes, FM; Walsh, JP; Woo, TU, 2004) |
| "A number of investigations have provided a growing body of evidence of the involvement of the gamma-aminobutyric acid (GABA) transmitter system in the pathophysiology of schizophrenia and bipolar disorder." | 3.72 | Immunohistochemical and immunoblot study of GABA(A) alpha1 and beta2/3 subunits in the prefrontal cortex of subjects with schizophrenia and bipolar disorder. ( Asada, T; Hidaka, S; Ishikawa, M; Iwakiri, M; Mizukami, K, 2004) |
| "We evaluated effectiveness and predictors of response of gabapentin (GBP) as adjunctive treatment in a sample of 43 subjects with DSM-III-R bipolar disorder who were resistant to standard mood stabilizers." | 3.71 | Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? ( Akiskal, HS; Frare, F; Moretti, L; Perugi, G; Ruffolo, G; Toni, C; Torti, C, 2002) |
| "The aim of the present study was to assess the efficacy of adjunctive gabapentin (GBP) in the treatment of patients with intellectual disability (ID) and bipolar spectrum disorders." | 3.71 | Adjunctive gabapentin in patients with intellectual disability and bipolar spectrum disorders. ( Carpiniello, B; Carta, MG; Dessì, I; Hardoy, MC; Hardoy, MJ, 2001) |
| "To determine if gabapentin is effective in monotherapy or add-on treatment of non-refractory bipolar disorder in open prospective treatment." | 3.71 | Gabapentin treatment of the non-refractory bipolar spectrum: an open case series. ( Ghaemi, SN; Goodwin, FK, 2001) |
| "To determine if gabapentin is effective either as adjunctive treatment or as monotherapy for major affective disorders in a naturalistic setting." | 3.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "All charts of patients meeting DSM-IV criteria for bipolar disorder or unipolar major depressive disorder treated with gabapentin in a private psychiatric practice were reviewed and clinical response was assessed retrospectively using the Clinical Global Impressions scale for Improvement (CGI-I)." | 3.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "Gabapentin was moderately to markedly effective in 30% (15/50) of patients, with statistically nonsignificant differences between patients with bipolar disorder type I, bipolar disorder type II and NOS, and unipolar major depressive disorder." | 3.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "Gabapentin appears to be somewhat effective as add-on treatment in a subgroup of patients with mood disorders in a naturalistic setting." | 3.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "Considerable evidence implicates the neurotransmitter gamma-aminobutyric acid (GABA) in the biochemical pathophysiology of mood disorders." | 3.70 | GABAA alpha-1 subunit gene not associated with depressive symptomatology in mood disorders. ( Catalano, M; Cusin, C; Di Bella, D; Lattuada, E; Lilli, R; Macciardi, F; Serretti, A; Smeraldi, E, 1998) |
| "To evaluate the efficacy of gabapentin as an adjunctive treatment for bipolar disorder in both depressed and manic phases." | 3.70 | Gabapentin as an adjunctive treatment in bipolar disorder. ( Hasey, GM; Joffe, RT; MacQueen, GM; Marriott, M; Patelis Siotis, I; Robb, JC; Young, LT, 1999) |
| "These findings are consistent with others in establishing the efficacy of gabapentin in both phases of bipolar disorder." | 3.70 | Gabapentin as an adjunctive treatment in bipolar disorder. ( Hasey, GM; Joffe, RT; MacQueen, GM; Marriott, M; Patelis Siotis, I; Robb, JC; Young, LT, 1999) |
| "This report describes the results of maintenance treatment with gabapentin in 18 previously refractory Bipolar Disorder patients who initially responded to augmentation with gabapentin during the acute phase of their therapy." | 3.70 | Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment. ( Schaffer, CB; Schaffer, LC, 1999) |
| "The authors measured gamma-aminobutyric acid (GABA) levels in the lumbar CSF of patients with depression, with psychosis, or undergoing evaluation for a neurologic disorder." | 3.66 | GABA levels in CSF of patients with psychiatric disorders. ( Bowers, MB; Gold, BI; Roth, RH; Sweeney, DW, 1980) |
| "A study of 246 patients (with schizophrenia, manic depressive psychoses and psychoorganic syndrome) treated by some drugs of a metabolic action (encephalotropic", "nootropic" drugs, piracetam, piriditol and pantogam) permitted one to determine the place of these preparations in a comprehensive treatment of mental disorders." | 3.66 | [Certain principles for differential utilization of metabolic treatment preparations in the complex therapy of mental disorders]. ( Avrutskiĭ, GIa; Laskova, NB, 1979) |
| "Gabapentin is a safe and well-tolerated medication, FDA-approved to treat other neurological diseases, that restores GABA/glutamate homeostasis, with treatment studies supporting efficacy in treating CUD, as well as anxiety and sleep disorders that are common to both BD and CUD." | 3.11 | Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders. ( Arnold, L; Hix, S; Mellick, W; Prisciandaro, JJ; Squeglia, LM; Tolliver, BK, 2022) |
| " This study examined the single-dose pharmacokinetic profiles of Li in 13 patients receiving placebo and then steady-state gabapentin (mean daily dose: 3,646." | 2.69 | Gabapentin does not alter single-dose lithium pharmacokinetics. ( Corá-Locatelli, G; Dunn, RT; Frye, MA; Grothe, D; Ketter, TA; Kimbrell, TA; Piscitelli, S; Post, RM; Vanderham, E, 1998) |
| "Gabapentin was effective in the treatment of mania and hypomania in patients with bipolar and schizoaffective disorders." | 2.69 | Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study. ( Cabras, PL; Carta, MG; Hardoy, MC; Hardoy, MJ, 1999) |
| "Gabapentin is a new adjunctive medication to antiseizure therapies." | 2.69 | Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology. ( DeMet, EM; Green, C; Maris, DE; Sokolski, KN, 1999) |
| "Gabapentin was well tolerated by all patients, with the most common side-effect being sedation." | 2.69 | Gabapentin in the acute treatment of refractory bipolar disorder. ( Altshuler, LL; Brown, ES; Denicoff, K; Frye, M; Gitlin, M; Goodman, R; Hwang, S; Keck, PE; Kupka, R; Leverich, G; McElroy, SL; Nolen, W; Post, R; Suppes, T, 1999) |
| "Fourteen of the 18 (78%) treated for hypomania or mania had a positive response to a dosage range of 600-3,600 mg/day." | 2.69 | Gabapentin in the acute treatment of refractory bipolar disorder. ( Altshuler, LL; Brown, ES; Denicoff, K; Frye, M; Gitlin, M; Goodman, R; Hwang, S; Keck, PE; Kupka, R; Leverich, G; McElroy, SL; Nolen, W; Post, R; Suppes, T, 1999) |
| "Gabapentin has been extensively prescribed off-label for psychiatric indications, with little established evidence of efficacy." | 2.55 | Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. ( Atkinson, LZ; Awad, A; Cipriani, A; Forrest, A; Geddes, JR; Harrison, PJ; Houghton, KT; Stockton, S, 2017) |
| "Eligible RCTs examined gabapentin for neuropathic pain and quetiapine for bipolar depression, reported in public (e." | 2.55 | Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis. ( Canner, JK; Dickersin, K; Fusco, N; Hong, H; Li, T; Mayo-Wilson, E, 2017) |
| "Eligible RCTs examined gabapentin for neuropathic pain and quetiapine for bipolar depression, reported in public (e." | 2.55 | Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy. ( Bertizzolo, L; Canner, JK; Cowley, T; Dickersin, K; Doshi, P; Ehmsen, J; Fusco, N; Gresham, G; Guo, N; Haythornthwaite, JA; Heyward, J; Hong, H; Li, T; Mayo-Wilson, E; Payne, JL; Pham, D; Rosman, L; Stuart, EA; Suarez-Cuervo, C; Tolbert, E; Twose, C; Vedula, S, 2017) |
| "Pediatric epilepsy is a common, chronic, and challenging physical illness for children and their families." | 2.46 | Psychiatric concerns in pediatric epilepsy. ( Bujoreanu, IS; DeMaso, DR; Ibeziako, P, 2010) |
| "Lamotrigine has demonstrated efficacy in delaying time to depressive relapse." | 2.42 | Rethinking the treatment paradigm for bipolar depression: the importance of long-term management. ( Baldassano, CF; Ballas, CA; O'Reardon, JP, 2004) |
| "The incidence of melanoma is rising rapidly, and the use of this regimen is becoming increasingly common." | 2.41 | Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. ( Everett, JR; Gadd, MA; Greenberg, DB; Haluska, FG; Jonasch, E; Mihm, MA; Ott, M; Ryan, BF; Sober, AJ; Tanabe, KK, 2000) |
| "Lamotrigine has demonstrated efficacy in both acute bipolar depression and maintenance efficacy in rapid cycling bipolar patients, especially those patients with bipolar II disorder, which is principally manifested as depression." | 2.41 | Novel treatments for bipolar disorder. ( Bowden, CL, 2001) |
| " Similarly, valproate combined with antipsychotics provided greater improvement in mania than antipsychotic medication alone and resulted in lower dosage of the antipsychotic medication." | 2.41 | Novel treatments for bipolar disorder. ( Bowden, CL, 2001) |
| "Topiramate has shown encouraging results in both depressed and manic bipolar patients, and it may also promote weight loss." | 2.41 | Bipolar disorders and the effectiveness of novel anticonvulsants. ( Calabrese, JR; Kimmel, SE; Rapport, DJ; Shelton, MD, 2002) |
| "Lamotrigine has positive effects on cognitive function, but occasionally produces insomnia." | 2.41 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| " A slow upward dose titration is recommended to reduce the incidence of serious rash, but this may delay the attainment of adequate dosage for 6 weeks." | 2.41 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| " One general rule that may reduce the risks of toxic drug interactions is to add medication to the patient's current regimen in modest doses and increase the dose slowly." | 2.40 | Mood stabilizer combinations: a review of safety and efficacy. ( Freeman, MP; Stoll, AL, 1998) |
| "Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders." | 2.40 | Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999) |
| " Lamotrigine may offer a much-needed treatment alternative for bipolar depression and could be found effective for acute mania, but the need for slow dosage adjustment and the risk of rash may limit overall clinical utility." | 2.40 | Gabapentin and lamotrigine in bipolar disorder. ( Botts, SR; Raskind, J, 1999) |
| "Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function." | 2.36 | Pharmacology of GABA. ( Meldrum, B, 1982) |
| "Brexanolone has been approved for the treatment of postpartum depression, ganaxolone is being studied for treatment-resistant depression, and gaboxadol development for the treatment of insomnia has been abandoned due to narrow therapeutic index." | 1.62 | Extra-synaptic modulation of GABA ( Ali, Z; El-Mallakh, RS, 2021) |
| "Schizophrenia is genetically highly heterogeneous, involving severe ultrarare mutations in genes that are critical to synaptic plasticity." | 1.56 | Genetics of schizophrenia in the South African Xhosa. ( Andrews, HF; Baldinger, A; Casadei, S; Fader, KM; Feng, M; Gibbs, RA; Gulsuner, S; Gur, RC; King, MC; Korchina, V; Majara, L; Malan, M; McClellan, JM; Mndini, MM; Mqulwana, SG; Muzny, D; Nagdee, M; Ngqengelele, LL; Ntola, OA; Pretorius, A; Ramesar, RS; Sibeko, G; Stein, DJ; Susser, ES; van der Merwe, C; Walsh, T; Willoughby, E; Zingela, Z, 2020) |
| "Gamma-aminobutyric acid (GABA) is a major inhibitory neurotransmitter." | 1.39 | Reduced GAD(65/67) immunoreactivity in the hypothalamic paraventricular nucleus in depression: a postmortem study. ( Bao, AM; Gao, SF; Klomp, A; Swaab, DF; Wu, JL, 2013) |
| "Drugs that are effective in treating the manic phase of bipolar disorder (lithium, carbamazepine, and valproate) upon chronic administration to rats decrease the turnover of arachidonic acid in their brain phospholipids." | 1.34 | Chronic lamotrigine does not alter the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat: implications for the treatment of bipolar disorder. ( Bazinet, RP; Chang, L; Lee, HJ; Rao, JS; Rapoport, SI, 2007) |
| " Past reports have suggested that some withdrawal symptoms can present after 1-2 days upon abrupt discontinuation of gabapentin after chronic use within young to middle-aged patients." | 1.33 | Gabapentin withdrawal syndrome in the presence of a taper. ( Hranicky, D; Jacob, Nj; Lark, T; Tran, KT, 2005) |
| "The patient displayed unique withdrawal symptoms after the taper of gabapentin." | 1.33 | Gabapentin withdrawal syndrome in the presence of a taper. ( Hranicky, D; Jacob, Nj; Lark, T; Tran, KT, 2005) |
| "Past reports have suggested that some withdrawal symptoms can present after 1-2 days upon abrupt discontinuation of gabapentin after chronic use within young to middle-aged patients." | 1.33 | Gabapentin withdrawal syndrome in the presence of a taper. ( Hranicky, D; Jacob, Nj; Lark, T; Tran, KT, 2005) |
| "Gabapentin appears to be a safe and effective treatment in geriatric mania when combined with antipsychotic medications or valproate." | 1.32 | Gabapentin in geriatric mania. ( Devanand, DP; Mehta, R; Sethi, MA, 2003) |
| " Mean dosage +/- SD at week 8 was 1270 +/- 561." | 1.31 | Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? ( Akiskal, HS; Frare, F; Moretti, L; Perugi, G; Ruffolo, G; Toni, C; Torti, C, 2002) |
| "Gabapentin is a relatively new anticonvulsant indicated for adjunctive therapy in the treatment of partial seizures, with and without secondary generalization, in adults with epilepsy." | 1.31 | Anorgasmia in a patient with bipolar disorder type 1 treated with gabapentin. ( Brannon, GE; Rolland, PD, 2000) |
| "Gabapentin was associated with a 43." | 1.31 | Gabapentin treatment of the non-refractory bipolar spectrum: an open case series. ( Ghaemi, SN; Goodwin, FK, 2001) |
| "Gabapentin is an anticonvulsant drug released in the United States in 1993 for use as adjunctive therapy in refractory partial epilepsy." | 1.31 | Gabapentin and methylphenidate treatment of a preadolescent with attention deficit hyperactivity disorder and bipolar disorder. ( Bailey, K; Hamrin, V, 2001) |
| "Gabapentin is an anticonvulsant proposed to have mood-stabilizing properties." | 1.30 | Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania. ( Knoll, J; Stegman, K; Suppes, T, 1998) |
| "Gabapentin was added openly, and rating was nonblind in this case series." | 1.30 | Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania. ( Knoll, J; Stegman, K; Suppes, T, 1998) |
| " Dosage and side effects were noted." | 1.30 | Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania. ( Knoll, J; Stegman, K; Suppes, T, 1998) |
| "Gabapentin is a new antiepileptic drug with an unknown mechanism of action and very favorable pharmacokinetic and safety profiles." | 1.30 | Gabapentin in the treatment of adolescent mania: a case report. ( Casuto, LS; Keck, PE; Soutullo, CA, 1998) |
| "Gabapentin was moderately to markedly effective in 30% (15/50) of patients, with statistically nonsignificant differences between patients with bipolar disorder type I, bipolar disorder type II and NOS, and unipolar major depressive disorder." | 1.30 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "Symptoms consistent with bruxism are a common chief complaint in dental practice." | 1.30 | Antidepressant-induced bruxism successfully treated with gabapentin. ( Brown, ES; Hong, SC, 1999) |
| "A case of bruxism, anxiety, insomnia and tremor is reported in a man with bipolar disorder that developed a few days after he initiated venlafaxine therapy for depression." | 1.30 | Antidepressant-induced bruxism successfully treated with gabapentin. ( Brown, ES; Hong, SC, 1999) |
| "Patients with unipolar depression who received a dexamethasone suppression test had no correlation between nonsuppression of cortisol secretion and plasma levels of GABA." | 1.27 | Plasma GABA levels in psychiatric illness. ( Petty, F; Sherman, AD, 1984) |
| "Carbamazepine was administered to nine patients with manic-depressive illness at doses ranging from 600 to 1600 mg per day, achieving blood levels between 6 and 11 microgram per milliliter." | 1.26 | Lack of effect of carbamazepine on gamma-aminobutyric acid in cerebrospinal fluid. ( Ballenger, JC; Bunney, WE; Hare, TA; Post, RM, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 33 (13.87) | 18.7374 |
| 1990's | 56 (23.53) | 18.2507 |
| 2000's | 92 (38.66) | 29.6817 |
| 2010's | 51 (21.43) | 24.3611 |
| 2020's | 6 (2.52) | 2.80 |
| Authors | Studies |
|---|---|
| Lybech, LKM | 1 |
| Calabró, M | 1 |
| Briuglia, S | 1 |
| Drago, A | 1 |
| Crisafulli, C | 1 |
| Hong, JSW | 1 |
| Atkinson, LZ | 2 |
| Al-Juffali, N | 1 |
| Awad, A | 2 |
| Geddes, JR | 2 |
| Tunbridge, EM | 1 |
| Harrison, PJ | 2 |
| Cipriani, A | 2 |
| Lu, Z | 1 |
| Wang, H | 1 |
| Gu, J | 1 |
| Gao, F | 1 |
| Gulsuner, S | 1 |
| Stein, DJ | 1 |
| Susser, ES | 1 |
| Sibeko, G | 1 |
| Pretorius, A | 1 |
| Walsh, T | 1 |
| Majara, L | 1 |
| Mndini, MM | 1 |
| Mqulwana, SG | 1 |
| Ntola, OA | 1 |
| Casadei, S | 1 |
| Ngqengelele, LL | 1 |
| Korchina, V | 1 |
| van der Merwe, C | 1 |
| Malan, M | 1 |
| Fader, KM | 1 |
| Feng, M | 1 |
| Willoughby, E | 1 |
| Muzny, D | 1 |
| Baldinger, A | 1 |
| Andrews, HF | 1 |
| Gur, RC | 1 |
| Gibbs, RA | 1 |
| Zingela, Z | 1 |
| Nagdee, M | 1 |
| Ramesar, RS | 1 |
| King, MC | 1 |
| McClellan, JM | 1 |
| El-Mallakh, RS | 1 |
| Ali, Z | 1 |
| Prisciandaro, JJ | 1 |
| Mellick, W | 1 |
| Squeglia, LM | 1 |
| Hix, S | 1 |
| Arnold, L | 1 |
| Tolliver, BK | 1 |
| Houghton, KT | 1 |
| Forrest, A | 1 |
| Stockton, S | 1 |
| Mayo-Wilson, E | 4 |
| Fusco, N | 4 |
| Li, T | 4 |
| Hong, H | 3 |
| Canner, JK | 2 |
| Dickersin, K | 6 |
| Huber, RS | 1 |
| Kondo, DG | 1 |
| Shi, XF | 1 |
| Prescot, AP | 2 |
| Clark, E | 1 |
| Renshaw, PF | 6 |
| Yurgelun-Todd, DA | 1 |
| Bertizzolo, L | 1 |
| Cowley, T | 2 |
| Doshi, P | 2 |
| Ehmsen, J | 2 |
| Gresham, G | 2 |
| Guo, N | 1 |
| Haythornthwaite, JA | 1 |
| Heyward, J | 2 |
| Pham, D | 1 |
| Payne, JL | 2 |
| Rosman, L | 2 |
| Stuart, EA | 2 |
| Suarez-Cuervo, C | 2 |
| Tolbert, E | 2 |
| Twose, C | 2 |
| Vedula, S | 2 |
| Romeo, B | 1 |
| Choucha, W | 1 |
| Fossati, P | 1 |
| Rotge, JY | 1 |
| Szulc, A | 1 |
| Wiedlocha, M | 1 |
| Waszkiewicz, N | 2 |
| Galińska-Skok, B | 1 |
| Marcinowicz, P | 1 |
| Gierus, J | 1 |
| Mosiolek, A | 1 |
| Wilczyńska, K | 1 |
| Simonienko, K | 1 |
| Konarzewska, B | 1 |
| Szajda, SD | 1 |
| Arrúe, A | 2 |
| González-Torres, MA | 2 |
| Basterreche, N | 2 |
| Arnaiz, A | 1 |
| Olivas, O | 1 |
| Zamalloa, MI | 2 |
| Erkoreka, L | 1 |
| Catalán, A | 1 |
| Zumárraga, M | 2 |
| Hui, J | 1 |
| Tremblay, S | 1 |
| Daskalakis, ZJ | 2 |
| Wu, TN | 1 |
| Chen, CK | 1 |
| Lee, CS | 1 |
| Wu, BJ | 1 |
| Sun, HJ | 1 |
| Chang, CH | 1 |
| Chen, CY | 1 |
| Wu, LS | 1 |
| Cheng, AT | 1 |
| Yukawa, T | 1 |
| Suzuki, Y | 1 |
| Fukui, N | 1 |
| Otake, M | 1 |
| Sugai, T | 1 |
| Someya, T | 1 |
| Brady, RO | 1 |
| McCarthy, JM | 1 |
| Jensen, JE | 2 |
| Cooper, AJ | 1 |
| Cohen, BM | 1 |
| Ongür, D | 2 |
| De Berardis, D | 1 |
| Serroni, N | 1 |
| Moschetta, FS | 1 |
| Martinotti, G | 1 |
| Di Giannantonio, M | 1 |
| Godlewska, BR | 1 |
| Yip, SW | 1 |
| Near, J | 1 |
| Goodwin, GM | 1 |
| Cowen, PJ | 2 |
| Mann, JJ | 1 |
| Oquendo, MA | 1 |
| Watson, KT | 1 |
| Boldrini, M | 1 |
| Malone, KM | 1 |
| Ellis, SP | 1 |
| Sullivan, G | 1 |
| Cooper, TB | 1 |
| Xie, S | 1 |
| Currier, D | 1 |
| Kalia, M | 1 |
| Costa E Silva, J | 1 |
| Dong, E | 3 |
| Ruzicka, WB | 2 |
| Grayson, DR | 4 |
| Guidotti, A | 5 |
| Schubert, KO | 1 |
| Föcking, M | 1 |
| Cotter, DR | 1 |
| Subburaju, S | 5 |
| Benes, FM | 13 |
| Kimoto, S | 1 |
| Zaki, MM | 1 |
| Bazmi, HH | 1 |
| Lewis, DA | 3 |
| Sikoglu, EM | 2 |
| Navarro, AA | 1 |
| Starr, D | 1 |
| Dvir, Y | 1 |
| Nwosu, BU | 1 |
| Czerniak, SM | 1 |
| Rogan, RC | 1 |
| Castro, MC | 1 |
| Edden, RA | 2 |
| Frazier, JA | 1 |
| Moore, CM | 2 |
| Soeiro-de-Souza, MG | 1 |
| Henning, A | 1 |
| Machado-Vieira, R | 1 |
| Moreno, RA | 1 |
| Pastorello, BF | 1 |
| da Costa Leite, C | 1 |
| Vallada, H | 1 |
| Otaduy, MC | 1 |
| Hutfless, S | 1 |
| Lock, D | 1 |
| Haythornthwaite, J | 1 |
| Singh, S | 1 |
| Wu, JL | 2 |
| Yu, SY | 1 |
| Wu, SH | 1 |
| Bao, AM | 3 |
| Ruiz-Veguilla, M | 1 |
| Martín-Rodríguez, JF | 1 |
| Palomar, FJ | 1 |
| Porcacchia, P | 1 |
| Álvarez de Toledo, P | 1 |
| Perona-Garcelán, S | 1 |
| Rodríguez-Testal, JF | 1 |
| Huertas-Fernández, I | 1 |
| Mir, P | 1 |
| Volk, DW | 1 |
| Sampson, AR | 1 |
| Zhang, Y | 1 |
| Edelson, JR | 1 |
| Mechawar, N | 1 |
| Savitz, J | 1 |
| Atagün, Mİ | 1 |
| Soykan, Ç | 1 |
| Serdar Süleyman, C | 1 |
| Ulusoy-Kaymak, S | 1 |
| Çayköylü, A | 1 |
| Algın, O | 1 |
| Phillips, ML | 1 |
| Fountoulakis, KN | 1 |
| Giannakopoulos, P | 1 |
| Kövari, E | 1 |
| Bouras, C | 1 |
| Sümegi, A | 1 |
| Melvin, CL | 4 |
| Carey, TS | 3 |
| Goodman, F | 2 |
| Oldham, JM | 2 |
| Williams, JW | 2 |
| Ranney, LM | 4 |
| Whitener, L | 1 |
| Morgan, LC | 1 |
| Kish-Doto, J | 1 |
| Evans, WD | 2 |
| Squire, C | 1 |
| Williams, P | 1 |
| Kreps, G | 1 |
| Linden, T | 1 |
| Oldham, J | 1 |
| Lim, B | 3 |
| Matzilevich, D | 2 |
| Walsh, JP | 3 |
| Patel, NC | 1 |
| Cecil, KM | 1 |
| Strakowski, SM | 2 |
| Adler, CM | 1 |
| DelBello, MP | 1 |
| Kaufman, RE | 1 |
| Ostacher, MJ | 1 |
| Marks, EH | 1 |
| Simon, NM | 1 |
| Sachs, GS | 2 |
| Pollack, MH | 1 |
| Dávila, R | 1 |
| Goienetxea, B | 1 |
| Anguiano, JB | 1 |
| Guimón, J | 1 |
| Terbach, N | 1 |
| Williams, RS | 1 |
| Rutten, BP | 1 |
| Mill, J | 1 |
| Vedula, SS | 2 |
| Bero, L | 1 |
| Scherer, RW | 1 |
| Rosa, AR | 1 |
| Fountoulakis, K | 1 |
| Siamouli, M | 1 |
| Gonda, X | 1 |
| Vieta, E | 4 |
| Cherlyn, SY | 1 |
| Woon, PS | 1 |
| Liu, JJ | 1 |
| Ong, WY | 1 |
| Tsai, GC | 1 |
| Sim, K | 1 |
| Fullerton, CA | 2 |
| Busch, AB | 1 |
| Frank, RG | 1 |
| Bithell, A | 1 |
| Hsu, T | 1 |
| Kandanearatchi, A | 1 |
| Landau, S | 2 |
| Everall, IP | 1 |
| Tsuang, MT | 1 |
| Chana, G | 2 |
| Williams, BP | 1 |
| Bujoreanu, IS | 1 |
| Ibeziako, P | 1 |
| DeMaso, DR | 1 |
| Agam, G | 1 |
| Ben-Shachar, D | 1 |
| Auta, J | 2 |
| Chen, Y | 1 |
| Davis, JM | 4 |
| Gavin, DP | 1 |
| Matrisciano, F | 1 |
| Pinna, G | 1 |
| Satta, R | 1 |
| Sharma, RP | 1 |
| Tremolizzo, L | 1 |
| Tueting, P | 1 |
| Sibille, E | 1 |
| Morris, HM | 1 |
| Kota, RS | 1 |
| Puts, NA | 1 |
| Sheng, G | 1 |
| Demers, M | 1 |
| Zhao, J | 1 |
| Qi, XR | 1 |
| Kamphuis, W | 1 |
| Luchetti, S | 1 |
| Lou, JS | 1 |
| Swaab, DF | 2 |
| Conesa, ML | 1 |
| Rojo, LM | 1 |
| Plumed, J | 1 |
| Livianos, L | 1 |
| Daniele, S | 1 |
| Da Pozzo, E | 1 |
| Abelli, M | 1 |
| Panighini, A | 1 |
| Pini, S | 1 |
| Gesi, C | 1 |
| Lari, L | 1 |
| Cardini, A | 1 |
| Cassano, GB | 1 |
| Martini, C | 1 |
| Goldman, PS | 1 |
| Rona, IJ | 1 |
| Greene, TM | 1 |
| Astaneh, AN | 1 |
| Rezaei, O | 1 |
| Schaffer, LC | 3 |
| Schaffer, CB | 3 |
| Miller, AR | 1 |
| Manley, JL | 1 |
| Piekut, JA | 1 |
| Nordahl, TE | 1 |
| Chace, MJ | 1 |
| Zhang, F | 1 |
| Huskamp, HA | 1 |
| Gilden, D | 1 |
| Soumerai, SB | 1 |
| Gao, SF | 1 |
| Klomp, A | 1 |
| Reynolds, GP | 1 |
| Beasley, CL | 1 |
| Zhang, ZJ | 1 |
| Perugi, G | 2 |
| Toni, C | 2 |
| Frare, F | 1 |
| Ruffolo, G | 2 |
| Moretti, L | 1 |
| Torti, C | 1 |
| Akiskal, HS | 1 |
| Wang, PW | 3 |
| Santosa, C | 1 |
| Schumacher, M | 1 |
| Winsberg, ME | 1 |
| Strong, C | 1 |
| Ketter, TA | 6 |
| Ernst, CL | 1 |
| Goldberg, JF | 2 |
| Shelton, RC | 1 |
| Schuckit, MA | 1 |
| Kelsoe, JR | 1 |
| Braff, DL | 1 |
| Wilhelmsen, KC | 1 |
| Gnanadesikan, M | 1 |
| Freeman, MP | 2 |
| Gelenberg, AJ | 1 |
| Carta, MG | 4 |
| Hardoy, MC | 4 |
| Hardoy, MJ | 4 |
| Grunze, H | 4 |
| Carpiniello, B | 2 |
| Sethi, MA | 1 |
| Mehta, R | 1 |
| Devanand, DP | 1 |
| Dager, SR | 2 |
| Friedman, SD | 2 |
| Parow, A | 2 |
| Demopulos, C | 2 |
| Stoll, AL | 3 |
| Lyoo, IK | 2 |
| Dunner, DL | 2 |
| O'Donnell, BF | 1 |
| Hetrick, WP | 1 |
| Vohs, JL | 1 |
| Krishnan, GP | 1 |
| Carroll, CA | 1 |
| Shekhar, A | 1 |
| Woo, TU | 1 |
| Yatham, LN | 3 |
| Ishikawa, M | 1 |
| Mizukami, K | 1 |
| Iwakiri, M | 1 |
| Hidaka, S | 1 |
| Asada, T | 1 |
| Hirashima, F | 1 |
| Baldassano, CF | 1 |
| Ballas, CA | 1 |
| O'Reardon, JP | 1 |
| Wilson, MS | 1 |
| Heckers, S | 1 |
| Benes, F | 1 |
| Muzina, DJ | 1 |
| Elhaj, O | 1 |
| Gajwani, P | 1 |
| Gao, K | 1 |
| Calabrese, JR | 6 |
| Veldic, M | 2 |
| Zhang, X | 1 |
| Costa, E | 4 |
| Tran, KT | 1 |
| Hranicky, D | 1 |
| Lark, T | 1 |
| Jacob, Nj | 1 |
| Dean, B | 1 |
| Scarr, E | 1 |
| McLeod, M | 1 |
| Howland, RH | 1 |
| Goldstein, JM | 1 |
| Bowden, CL | 5 |
| Post, RM | 10 |
| Suppes, T | 5 |
| Choudary, PV | 1 |
| Molnar, M | 1 |
| Evans, SJ | 1 |
| Tomita, H | 1 |
| Li, JZ | 1 |
| Vawter, MP | 1 |
| Myers, RM | 1 |
| Bunney, WE | 3 |
| Akil, H | 1 |
| Watson, SJ | 1 |
| Jones, EG | 1 |
| Green, T | 1 |
| Shoval, G | 1 |
| Weizman, A | 1 |
| Manuel Goikolea, J | 1 |
| Martínez-Arán, A | 2 |
| Comes, M | 1 |
| Verger, K | 1 |
| Masramon, X | 1 |
| Sanchez-Moreno, J | 1 |
| Colom, F | 2 |
| Hellings, JA | 1 |
| Bialer, M | 1 |
| Saxena, K | 1 |
| Howe, M | 1 |
| Simeonova, D | 1 |
| Steiner, H | 1 |
| Chang, K | 1 |
| Bhagwagar, Z | 1 |
| Wylezinska, M | 1 |
| Jezzard, P | 1 |
| Evans, J | 1 |
| Ashworth, F | 1 |
| Sule, A | 1 |
| Matthews, PM | 1 |
| Silvia, RJ | 1 |
| Spitznas, AL | 1 |
| Kadriu, B | 1 |
| Maloku, E | 1 |
| Agis-Balboa, RC | 1 |
| Sajatovic, M | 1 |
| Ramsay, E | 1 |
| Nanry, K | 1 |
| Thompson, T | 1 |
| Bielau, H | 1 |
| Steiner, J | 1 |
| Mawrin, C | 1 |
| Trübner, K | 1 |
| Brisch, R | 1 |
| Meyer-Lotz, G | 1 |
| Brodhun, M | 1 |
| Dobrowolny, H | 1 |
| Baumann, B | 1 |
| Gos, T | 1 |
| Bernstein, HG | 1 |
| Bogerts, B | 1 |
| Buttner, N | 1 |
| Bhattacharyya, S | 1 |
| Walsh, J | 1 |
| Lee, HJ | 1 |
| Rao, JS | 1 |
| Chang, L | 1 |
| Rapoport, SI | 1 |
| Bazinet, RP | 1 |
| Minns, M | 1 |
| Collins, JC | 1 |
| McFarland, BH | 1 |
| Frey, BN | 1 |
| Andreazza, AC | 1 |
| Nery, FG | 1 |
| Martins, MR | 1 |
| Quevedo, J | 1 |
| Soares, JC | 1 |
| Kapczinski, F | 1 |
| Levinson, AJ | 1 |
| Young, LT | 4 |
| Fitzgerald, PB | 1 |
| Sakai, T | 1 |
| Oshima, A | 1 |
| Nozaki, Y | 1 |
| Ida, I | 1 |
| Haga, C | 1 |
| Akiyama, H | 1 |
| Nakazato, Y | 1 |
| Mikuni, M | 1 |
| Lan, MJ | 1 |
| McLoughlin, GA | 1 |
| Griffin, JL | 1 |
| Tsang, TM | 1 |
| Huang, JT | 1 |
| Yuan, P | 1 |
| Manji, H | 1 |
| Holmes, E | 1 |
| Bahn, S | 1 |
| Gerner, RH | 2 |
| Fairbanks, L | 1 |
| Anderson, GM | 1 |
| Young, JG | 1 |
| Scheinin, M | 1 |
| Linnoila, M | 1 |
| Hare, TA | 5 |
| Shaywitz, BA | 1 |
| Cohen, DJ | 1 |
| Meldrum, B | 1 |
| Petty, F | 7 |
| Sherman, AD | 1 |
| Garland, BL | 1 |
| Zivkovic, B | 1 |
| Scatton, B | 1 |
| Worms, P | 1 |
| Lloyd, KG | 1 |
| Bartholini, G | 1 |
| Uhde, TW | 1 |
| Ballenger, JC | 3 |
| Berrettini, WH | 6 |
| Nurnberger, JI | 6 |
| Simmons-Alling, S | 4 |
| Gershon, ES | 6 |
| Emrich, HM | 3 |
| Altmann, H | 1 |
| Dose, M | 1 |
| von Zerssen, D | 3 |
| Schlesser, MA | 1 |
| Kissling, W | 2 |
| Möller, HJ | 2 |
| Windorfer, A | 1 |
| Umberkoman-Wiita, B | 1 |
| Vogel, WH | 1 |
| Gillman, MA | 1 |
| Lichtigfeld, FJ | 1 |
| Kasa, K | 1 |
| Otsuki, S | 1 |
| Yamamoto, M | 1 |
| Sato, M | 1 |
| Kuroda, H | 1 |
| Ogawa, N | 1 |
| Cutler, NR | 1 |
| Hare, T | 1 |
| Gold, BI | 1 |
| Bowers, MB | 1 |
| Roth, RH | 1 |
| Sweeney, DW | 1 |
| Short, C | 1 |
| Cooke, L | 1 |
| Motohashi, N | 1 |
| Kramer, GL | 2 |
| Fulton, M | 1 |
| Moeller, FG | 1 |
| Rush, AJ | 2 |
| Kimmel, SE | 2 |
| Small, JG | 1 |
| Miller, MJ | 1 |
| Swann, AE | 1 |
| Orsulak, PJ | 1 |
| Blake, ME | 1 |
| Hauck, A | 1 |
| Bhaumik, S | 1 |
| De bruyn, A | 1 |
| Souery, D | 1 |
| Mendelbaum, K | 1 |
| Mendlewicz, J | 1 |
| Van Broeckhoven, C | 2 |
| Stanton, SP | 1 |
| Keck, PE | 5 |
| McElroy, SL | 4 |
| Ryback, RS | 1 |
| Brodsky, L | 1 |
| Munasifi, F | 1 |
| Oruc, L | 1 |
| Furac, I | 1 |
| Croux, C | 1 |
| Jakovljevic, M | 1 |
| Kracun, I | 1 |
| Folnegović, V | 1 |
| Soutullo, CA | 2 |
| Kmetz, GF | 1 |
| Robb, JC | 2 |
| Patelis-Siotis, I | 1 |
| MacDonald, C | 1 |
| Joffe, RT | 2 |
| Sheldon, LJ | 1 |
| Ancill, RJ | 1 |
| Holliday, SG | 1 |
| Knoll, J | 1 |
| Stegman, K | 1 |
| Casuto, LS | 1 |
| Tueth, MJ | 1 |
| Murphy, TK | 1 |
| Evans, DL | 1 |
| Blinder, BJ | 1 |
| Bhat, S | 1 |
| Sanathara, VA | 1 |
| Ghaemi, SN | 4 |
| Katzow, JJ | 1 |
| Desai, SP | 1 |
| Goodwin, FK | 3 |
| Xie, X | 1 |
| Hagan, RM | 1 |
| Ferrier, IN | 1 |
| Dittert, S | 1 |
| Bungert, M | 1 |
| Erfurth, A | 2 |
| Serretti, A | 1 |
| Macciardi, F | 1 |
| Cusin, C | 1 |
| Lattuada, E | 1 |
| Lilli, R | 1 |
| Di Bella, D | 1 |
| Catalano, M | 1 |
| Smeraldi, E | 1 |
| Frye, MA | 3 |
| Kimbrell, TA | 2 |
| Dunn, RT | 1 |
| Piscitelli, S | 1 |
| Grothe, D | 2 |
| Vanderham, E | 1 |
| Corá-Locatelli, G | 2 |
| Luckenbaugh, D | 1 |
| Constantino, C | 1 |
| Boiman, EE | 1 |
| Hatzimanolis, J | 1 |
| Lykouras, L | 1 |
| Oulis, P | 1 |
| Christodoulou, GN | 1 |
| Rosebush, PI | 1 |
| MacQueen, GM | 2 |
| Mazurek, MF | 1 |
| Cabras, PL | 2 |
| Letterman, L | 1 |
| Markowitz, JS | 1 |
| Labbate, LA | 1 |
| Rubey, RN | 1 |
| Lovell, RW | 1 |
| Amann, B | 1 |
| Normann, C | 1 |
| Walden, J | 1 |
| Sartini, S | 1 |
| Simonini, E | 1 |
| Akiskal, H | 1 |
| Hasey, GM | 1 |
| Patelis Siotis, I | 1 |
| Marriott, M | 1 |
| Mitchell, P | 1 |
| Magnus, L | 1 |
| Botts, SR | 1 |
| Raskind, J | 1 |
| Brown, ES | 2 |
| Hong, SC | 1 |
| Sokolski, KN | 1 |
| Green, C | 1 |
| Maris, DE | 1 |
| DeMet, EM | 1 |
| Meldrum, BS | 1 |
| Chapman, AG | 1 |
| Swann, AC | 1 |
| Dilsaver, SC | 1 |
| Morris, DD | 1 |
| Leweke, FM | 1 |
| Bauer, J | 1 |
| Elger, CE | 1 |
| Chaudron, LH | 1 |
| Jefferson, JW | 1 |
| Brannon, GE | 1 |
| Rolland, PD | 1 |
| Greenberg, DB | 1 |
| Jonasch, E | 1 |
| Gadd, MA | 1 |
| Ryan, BF | 1 |
| Everett, JR | 1 |
| Sober, AJ | 1 |
| Mihm, MA | 1 |
| Tanabe, KK | 1 |
| Ott, M | 1 |
| Haluska, FG | 1 |
| Bennett, J | 1 |
| Goldman, WT | 1 |
| Nieto, E | 1 |
| Reinares, M | 1 |
| Benabarre, A | 1 |
| Gastó, C | 1 |
| Janowsky, DS | 1 |
| Nemeroff, CB | 1 |
| Lindenmayer, JP | 1 |
| Alao, AO | 1 |
| Dewan, MJ | 1 |
| Todtenkopf, MS | 2 |
| Logiotatos, P | 1 |
| Williams, M | 1 |
| Pande, AC | 1 |
| Crockatt, JG | 1 |
| Janney, CA | 1 |
| Werth, JL | 1 |
| Tsaroucha, G | 1 |
| Montes, JM | 1 |
| Ferrando, L | 1 |
| Chengappa, KN | 2 |
| Rathore, D | 1 |
| Levine, J | 2 |
| Atzert, R | 1 |
| Solai, L | 1 |
| Parepally, H | 1 |
| Levin, H | 1 |
| Moffa, N | 1 |
| Delaney, J | 1 |
| Brar, JS | 1 |
| Altshuler, LL | 1 |
| Denicoff, K | 1 |
| Frye, M | 1 |
| Gitlin, M | 1 |
| Hwang, S | 1 |
| Goodman, R | 1 |
| Leverich, G | 1 |
| Nolen, W | 1 |
| Kupka, R | 1 |
| Post, R | 1 |
| Dessì, I | 1 |
| Berretta, S | 1 |
| Ginsberg, DL | 1 |
| Sussman, N | 2 |
| Burdick, KE | 1 |
| Pinninti, NR | 1 |
| Mahajan, DS | 1 |
| Ko, JY | 1 |
| Davis, J | 1 |
| Pappas, GD | 1 |
| Pesold, C | 1 |
| Hamrin, V | 1 |
| Bailey, K | 1 |
| Maidment, ID | 1 |
| Robillard, M | 1 |
| Conn, D | 1 |
| Kostoulakos, P | 1 |
| Cotter, D | 1 |
| Beasley, C | 1 |
| Stevenson, R | 1 |
| MacMillan, L | 1 |
| Everall, I | 1 |
| Shelton, MD | 1 |
| Rapport, DJ | 1 |
| Gershon, S | 1 |
| Hurley, SC | 1 |
| Kusumakar, V | 1 |
| Rao, R | 1 |
| Scarrow, G | 1 |
| Kroeker, G | 1 |
| Cosgrove, VE | 1 |
| Biancosino, B | 1 |
| Facchi, A | 1 |
| Marmai, L | 1 |
| Grassi, L | 1 |
| Macdonald, KJ | 1 |
| Li, X | 1 |
| Faull, KF | 1 |
| DoAmaral, JR | 1 |
| Berger, PA | 1 |
| Barchas, JD | 1 |
| Ananth, J | 1 |
| Vinar, O | 1 |
| Avrutskiĭ, GIa | 1 |
| Laskova, NB | 1 |
| Roy, A | 1 |
| Dejong, J | 1 |
| Ferraro, T | 1 |
| Meltzer, HL | 1 |
| Rubinow, DR | 1 |
| Gold, PW | 1 |
| Reichlin, S | 1 |
| Narrow, W | 1 |
| Hetmar, O | 1 |
| Nielsen, M | 1 |
| Borsook, D | 1 |
| Richardson, GS | 1 |
| Moore-Ede, MC | 1 |
| Brennan, MJ | 1 |
| Waldmeier, PC | 1 |
| Takahashi, R | 1 |
| Semba, J | 1 |
| Guroff, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gabapentin for Bipolar & Cannabis Use Disorders[NCT03334721] | Phase 2 | 23 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| A Phase I Randomized, Double-blinded, Placebo-controlled Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of HS-10353 in Chinese Adult Subjects[NCT05195203] | Phase 1 | 96 participants (Actual) | Interventional | 2021-01-27 | Completed | ||
| Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| The Efficacy of Gabapentine and Splint Therapy in Bruxers: a Randomized Clinical Trial[NCT01255878] | 20 participants (Actual) | Interventional | 2010-03-31 | Completed | |||
| Pilot Evaluation of Levetiracetam (Keppra® (Registered Trademark)) in Bipolar Illness[NCT00015769] | Phase 2 | 30 participants | Interventional | 2001-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA, normalized to water and corrected for CSF%, in dorsal anterior cingulate measured via Proton Magnetic Resonance Spectroscopy. (NCT03334721)
Timeframe: Day 5 of each experimental condition
| Intervention | Institutional Units (Mean) | |
|---|---|---|
| GABA (randomization order 1, gabapentin 1st) | GABA (randomization order 2, placebo 1st) | |
| Gabapentin | 2.625 | 2.609 |
| Placebo Oral Capsule | 2.696 | 2.720 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 | -15.5 |
| Arm 2 | -15.5 |
Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks
| Intervention | kilograms (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 6 | Week 8 | |
| Arm 1- ODT | 76.0 | 77.4 | 77.8 | 78.9 | 79.1 |
| Arm 2- SOT | 76.1 | 77.6 | 78.3 | 79.4 | 80.1 |
80 reviews available for gamma-aminobutyric acid and Bipolar Disorder
| Article | Year |
|---|---|
Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale.
Topics: Amines; Anxiety; Bipolar Disorder; Calcium Channels; Cyclohexanecarboxylic Acids; Gabapentin; gamma- | 2022 |
Association between abnormal brain oscillations and cognitive performance in patients with bipolar disorder: Molecular mechanisms and clinical evidence.
Topics: Biomarkers; Bipolar Disorder; Brain; Cadherins; Calcium; Cognition; Electroencephalography; gamma-Am | 2022 |
Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis.
Topics: Amines; Anti-Anxiety Agents; Anxiety Disorders; Bipolar Disorder; Cyclohexanecarboxylic Acids; Doubl | 2017 |
Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis.
Topics: Amines; Analgesics; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapentin; | 2017 |
Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy.
Topics: Amines; Bias; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hu | 2017 |
Meta-analysis of central and peripheral γ-aminobutyric acid levels in patients with unipolar and bipolar depression.
Topics: Adolescent; Adult; Aged; Biomarkers; Bipolar Disorder; Brain; Depressive Disorder, Major; Female; ga | 2018 |
Proton magnetic resonance spectroscopy changes after lithium treatment. Systematic review.
Topics: Antimanic Agents; Aspartic Acid; Bipolar Disorder; Brain; Choline; Cross-Sectional Studies; gamma-Am | 2018 |
Morphological changes of the brain in mood disorders.
Topics: Bipolar Disorder; Brain; gamma-Aminobutyric Acid; Humans; Mood Disorders; Neuroimaging; Neurons | 2018 |
The Current and Future Potential of Transcranial Magnetic Stimulation With Electroencephalography in Psychiatry.
Topics: Biomarkers; Bipolar Disorder; Depressive Disorder, Major; Electroencephalography; Frontal Lobe; gamm | 2019 |
Biomarkers of psychiatric diseases: current status and future prospects.
Topics: Acetyltransferases; Alzheimer Disease; Biomarkers; Bipolar Disorder; Brain; Brain-Derived Neurotroph | 2015 |
Neuropathology of mood disorders: do we see the stigmata of inflammation?
Topics: Astrocytes; Autoimmune Diseases of the Nervous System; Bipolar Disorder; Brain; Depressive Disorder, | 2016 |
Assessing the role of cingulate cortex in bipolar disorder: neuropathological, structural and functional imaging data.
Topics: Animals; Bipolar Disorder; Diagnostic Imaging; Functional Laterality; gamma-Aminobutyric Acid; Gyrus | 2008 |
[Mood stabilizers--past, present and future].
Topics: Affect; Antimanic Agents; Bipolar Disorder; Calcium; Carbamazepine; Depressive Disorder; gamma-Amino | 2008 |
Effectiveness of antiepileptic drugs for the treatment of bipolar disorder: findings from a systematic review.
Topics: Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Drug-Related Side Effects an | 2008 |
Gabapentin in the treatment of mental illness: the echo chamber of the case series.
Topics: Amines; Anticonvulsants; Bipolar Disorder; Conflict of Interest; Cyclohexanecarboxylic Acids; Drug E | 2008 |
Applications for magnetic resonance imaging in bipolar disorder.
Topics: Antipsychotic Agents; Aspartic Acid; Bipolar Disorder; Brain; gamma-Aminobutyric Acid; Glutamic Acid | 2007 |
Structure-function studies for the panacea, valproic acid.
Topics: Animals; Anticonvulsants; Bipolar Disorder; Epilepsy; gamma-Aminobutyric Acid; Glycogen Synthase Kin | 2009 |
Epigenetic mediation of environmental influences in major psychotic disorders.
Topics: Alleles; Bipolar Disorder; Child; Child Abuse; Diseases in Twins; DNA Methylation; Epigenesis, Genet | 2009 |
Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials.
Topics: Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Cy | 2011 |
Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance.
Topics: Animals; Bipolar Disorder; gamma-Aminobutyric Acid; Genetic Association Studies; Glutamic Acid; Huma | 2010 |
Psychiatric concerns in pediatric epilepsy.
Topics: Adolescent; Amines; Anxiety Disorders; Bipolar Disorder; Child; Child, Preschool; Cyclohexanecarboxy | 2010 |
Epigenetic GABAergic targets in schizophrenia and bipolar disorder.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Epigenesis, Genetic; Excitatory Amino Acid Agents; | 2011 |
In vivo magnetic resonance spectroscopy of GABA: a methodological review.
Topics: Bipolar Disorder; Depressive Disorder, Major; Epilepsy; gamma-Aminobutyric Acid; Humans; Magnetic Re | 2012 |
Nicotinic receptors and functional regulation of GABA cell microcircuitry in bipolar disorder and schizophrenia.
Topics: Bipolar Disorder; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Hippocampus; Humans; Interneuron | 2012 |
Antidepressant properties of anticonvulsant drugs for bipolar disorder.
Topics: Acetates; Affect; Amines; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Carbamazepine; C | 2003 |
The emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combin | 2003 |
Treating bipolar depression.
Topics: Acetates; Affect; Amines; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; | 2003 |
Alternatives to lithium and divalproex in the maintenance treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar | 2003 |
The clinical use of gabapentin in bipolar spectrum disorders.
Topics: Acetates; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapentin; gamma | 2003 |
Newer anticonvulsants in the treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Dep | 2004 |
Rethinking the treatment paradigm for bipolar depression: the importance of long-term management.
Topics: Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Ch | 2004 |
Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder.
Topics: Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Cyclohexa | 2005 |
GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon.
Topics: Animals; Benzodiazepines; Bipolar Disorder; Cell Adhesion Molecules, Neuronal; Cerebral Cortex; Chlo | 2005 |
Anticonvulsant drug therapies.
Topics: Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Depressive Di | 2005 |
[The treatment of mood stabilizers in children and adolescents suffering from bipolar affective disorder].
Topics: Adolescent; Adult; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Child; Cyclohexaneca | 2005 |
New antiepileptic drugs that are second generation to existing antiepileptic drugs.
Topics: Amines; Animals; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Drug | 2006 |
Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia.
Topics: Aged; Aged, 80 and over; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2007 |
Searching for unique endophenotypes for schizophrenia and bipolar disorder within neural circuits and their molecular regulatory mechanisms.
Topics: Amygdala; Antioxidants; Bipolar Disorder; Calcium Channels, L-Type; Down-Regulation; gamma-Aminobuty | 2007 |
The role of hippocampus in the pathophysiology of bipolar disorder.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Disease Models, Animal; gamma-Aminobutyric Acid; Glutam | 2007 |
Use of the anticonvulsant carbamazepine in primary and secondary affective illness: clinical and theoretical implications.
Topics: Affective Disorders, Psychotic; Animals; Antidepressive Agents; Antipsychotic Agents; Bipolar Disord | 1982 |
Pharmacology of GABA.
Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep | 1982 |
[Anti-anxiety drug therapy of bipolar disorders--clinical and basic study].
Topics: Adult; Aged; Animals; Anti-Anxiety Agents; Bipolar Disorder; Female; gamma-Aminobutyric Acid; Humans | 1993 |
Plasma concentrations of gamma-aminobutyric acid (GABA) and mood disorders: a blood test for manic depressive disease?
Topics: Affective Disorders, Psychotic; Bipolar Disorder; Brain; Drug Stability; gamma-Aminobutyric Acid; Hu | 1994 |
GABA and mood disorders: a brief review and hypothesis.
Topics: Biomarkers; Bipolar Disorder; Brain Stem; Depressive Disorder; gamma-Aminobutyric Acid; Hippocampus; | 1995 |
Association study between bipolar disorder and candidate genes involved in dopamine-serotonin metabolism and GABAergic neurotransmission: a preliminary report.
Topics: Bipolar Disorder; Chromosome Mapping; gamma-Aminobutyric Acid; Humans; Polymorphism, Genetic; Recept | 1996 |
Mood stabilizer combinations: a review of safety and efficacy.
Topics: Acetates; Amines; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Calcium Channel Blockers; | 1998 |
Special considerations: use of lithium in children, adolescents, and elderly populations.
Topics: Abnormalities, Drug-Induced; Acetates; Adolescent; Adult; Age Factors; Aged; Amines; Anticonvulsants | 1998 |
Anticonvulsants and antipsychotics in the treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Clinical T | 1998 |
Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder.
Topics: Acetates; Action Potentials; Amines; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipol | 1998 |
Lamotrigine and gabapentin. Alternative in the treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Clinic | 1998 |
Kindling and second messengers: an approach to the neurobiology of recurrence in bipolar disorder.
Topics: Acetylcholine; Bipolar Disorder; Cell Communication; gamma-Aminobutyric Acid; GTP-Binding Proteins; | 1999 |
Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions.
Topics: Acetates; Amines; Anticonvulsants; Anxiety; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapenti | 1999 |
Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states.
Topics: Acetates; Adjuvants, Pharmaceutic; Adult; Aged; Amines; Analysis of Variance; Antidepressive Agents; | 1999 |
Lamotrigine in the treatment of bipolar depression.
Topics: Acetates; Affect; Amines; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cross-Over Stud | 1999 |
Nonepileptic uses of gabapentin.
Topics: Acetates; Amines; Analgesics; Antimanic Agents; Antiparkinson Agents; Bipolar Disorder; Clinical Tri | 1999 |
Gabapentin and lamotrigine in bipolar disorder.
Topics: Acetates; Adult; Amines; Anticonvulsants; Bipolar Disorder; Clinical Trials as Topic; Cyclohexanecar | 1999 |
Basic mechanisms of gabitril (tiagabine) and future potential developments.
Topics: Animals; Anticonvulsants; Bipolar Disorder; Carrier Proteins; Epilepsy; GABA Antagonists; GABA Plasm | 1999 |
Mood stabilizers during breastfeeding: a review.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Breast Feeding; Carbamazepine; Cyclohexanecarbo | 2000 |
Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Antimanic Agents; Antineoplastic Agents; Bipolar Disor | 2000 |
New treatments of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Clinical Tri | 1999 |
An ever-increasing pharmacopoeia for the management of patients with bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamaz | 2000 |
The pathophysiology of agitation.
Topics: Aggression; Behavioral Symptoms; Bipolar Disorder; Dementia; Dopamine; gamma-Aminobutyric Acid; Huma | 2000 |
Novel treatments for bipolar disorder.
Topics: Acetates; Amines; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Therapy, Combin | 2001 |
GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder.
Topics: Animals; Bipolar Disorder; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Interneurons; Limbic Sy | 2001 |
Cognitive side effects of anticonvulsants.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cognition Disorders; Cyclohexane | 2001 |
Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability.
Topics: Adolescent; Adult; Age of Onset; Animals; Antigens, CD; Bipolar Disorder; Brain; Cell Adhesion Molec | 2001 |
Gabapentin treatment for bipolar disorders.
Topics: Acetates; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapentin; gamma | 2001 |
Predictors of treatment response in bipolar disorders: evidence from clinical and brain imaging studies.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Brain; Carbamazepine; gamma-Aminobutyric Acid; | 2002 |
Bipolar disorders and the effectiveness of novel anticonvulsants.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Fructose; Gabapent | 2002 |
The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder.
Topics: Acetates; Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2001 |
Lamotrigine update and its use in mood disorders.
Topics: Acetates; Aggression; Amines; Antidepressive Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; | 2002 |
Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Double-Blind Metho | 2002 |
Bipolar disorder: current treatments and new strategies.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Fructose; Gabapent | 1998 |
Background and rationale for use of anticonvulsants in psychiatry.
Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cycloh | 1998 |
Newer antiepileptic drugs in bipolar disorder: rationale for use and role in therapy.
Topics: Acetates; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Cyc | 2002 |
Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders?
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; gamma-Aminobutyric Acid; Gene Expression Regulatio | 2002 |
Treatment approaches to mania.
Topics: Acetylcholine; Antidepressive Agents, Tricyclic; Autonomic Nervous System; Biogenic Amines; Bipolar | 1976 |
[The significance of endorphins and gamma-aminobutyric acid in clinical psychopharmacology (author's transl)].
Topics: Anxiety; Bipolar Disorder; Deficiency Diseases; Depression; Endorphins; gamma-Aminobutyric Acid; Hum | 1978 |
Building a bridge between neurobiology and mental illness.
Topics: Bipolar Disorder; Brain; Brain Mapping; gamma-Aminobutyric Acid; Humans; Mental Disorders; Receptors | 1992 |
[Biochemistry of manic-depressive disorders (III)--Action mechanisms of therapeutic drugs].
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Disease Models, Animal; gamma-Aminobutyric Acid; H | 1988 |
30 trials available for gamma-aminobutyric acid and Bipolar Disorder
| Article | Year |
|---|---|
Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders.
Topics: Adolescent; Adult; Bipolar Disorder; Cigarette Smoking; Double-Blind Method; Female; Gabapentin; gam | 2022 |
Adjunctive treatment with gabapentin in bipolar patients during acute mania.
Topics: Acute Disease; Age Distribution; Amines; Analysis of Variance; Antimanic Agents; Bipolar Disorder; C | 2012 |
Gabapentin augmentation therapy in bipolar depression.
Topics: Acetates; Adult; Amines; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clozapine; Cycloh | 2002 |
Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder.
Topics: Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Brain; Brain Chemistry; Brain Mappi | 2004 |
A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder.
Topics: Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug Th | 2006 |
Much improved outcome with gabapentin-divalproex combination in adults with bipolar disorders and developmental disabilities.
Topics: Adolescent; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Developm | 2006 |
Divalproex sodium reduces overall aggression in youth at high risk for bipolar disorder.
Topics: Adolescent; Affect; Aggression; Antimanic Agents; Attention Deficit and Disruptive Behavior Disorder | 2006 |
Cortical inhibitory dysfunction in bipolar disorder: a study using transcranial magnetic stimulation.
Topics: Adult; Bipolar Disorder; Electromyography; Evoked Potentials, Motor; Female; Functional Laterality; | 2007 |
Use of the anticonvulsant carbamazepine in primary and secondary affective illness: clinical and theoretical implications.
Topics: Affective Disorders, Psychotic; Animals; Antidepressive Agents; Antipsychotic Agents; Bipolar Disord | 1982 |
The efficacy of carbamazepine in affective illness.
Topics: Antidepressive Agents; Bipolar Disorder; Carbamazepine; Central Nervous System; Clinical Trials as T | 1984 |
Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report.
Topics: Adolescent; Adult; Analgesics; Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as | 1983 |
Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Alcohol Withdrawal Delirium; Bipolar Disorder; Cl | 1980 |
Plasma GABA predicts acute response to divalproex in mania.
Topics: Adult; Aged; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Female; gamma-Aminobutyric Aci | 1996 |
Gabapentin in the treatment of bipolar disorder.
Topics: Acetates; Adult; Ambulatory Care; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic A | 1997 |
A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder.
Topics: Acetates; Adjuvants, Pharmaceutic; Adult; Affect; Amines; Anticonvulsants; Bipolar Disorder; Cyclohe | 1997 |
Gabapentin does not alter single-dose lithium pharmacokinetics.
Topics: Acetates; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Depression; Doubl | 1998 |
Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study.
Topics: Acetates; Acute Disease; Adult; Aged; Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agent | 1999 |
[Gabapentin in the treatment of mania].
Topics: Acetates; Amines; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clozapine; Cyclohexaneca | 1999 |
Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states.
Topics: Acetates; Adjuvants, Pharmaceutic; Adult; Aged; Amines; Analysis of Variance; Antidepressive Agents; | 1999 |
Lamotrigine in the treatment of bipolar depression.
Topics: Acetates; Affect; Amines; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cross-Over Stud | 1999 |
Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology.
Topics: Acetates; Adult; Affect; Aged; Ambulatory Care; Amines; Antidepressive Agents; Bipolar Disorder; Cyc | 1999 |
Mania: gender, transmitter function, and response to treatment.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Female; gamma-Aminobutyric Acid; Humans; Lithium Carbonat | 1999 |
Adjunctive gabapentin treatment of bipolar disorder.
Topics: Acetates; Adult; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic | 2000 |
Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic | 2000 |
Topiramate as add-on treatment for patients with bipolar mania.
Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Body Mass Index; | 1999 |
Gabapentin in the acute treatment of refractory bipolar disorder.
Topics: Acetates; Acute Disease; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Ac | 1999 |
The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder.
Topics: Acetates; Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2001 |
Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Double-Blind Metho | 2002 |
Effects of carbamazepine on cerebrospinal fluid somatostatin.
Topics: Adrenocorticotropic Hormone; Bipolar Disorder; Carbamazepine; Depressive Disorder; gamma-Aminobutyri | 1985 |
Intravenous GABA administration is anxiogenic in man.
Topics: Anxiety; Bipolar Disorder; Blood Pressure; gamma-Aminobutyric Acid; Heart Rate; Humans; Injections, | 1986 |
133 other studies available for gamma-aminobutyric acid and Bipolar Disorder
| Article | Year |
|---|---|
Suicide Related Phenotypes in a Bipolar Sample: Genetic Underpinnings.
Topics: Adult; Aged; Aminopeptidases; Bipolar Disorder; gamma-Aminobutyric Acid; Genetic Predisposition to D | 2021 |
Genetics of schizophrenia in the South African Xhosa.
Topics: Age Factors; Autistic Disorder; Bipolar Disorder; Dopamine; Female; gamma-Aminobutyric Acid; Genetic | 2020 |
Extra-synaptic modulation of GABA
Topics: Antimanic Agents; Bipolar Disorder; Depression, Postpartum; Female; gamma-Aminobutyric Acid; Humans; | 2021 |
Relationship of executive functioning deficits to N-acetyl aspartate (NAA) and gamma-aminobutyric acid (GABA) in youth with bipolar disorder.
Topics: Adolescent; Aspartic Acid; Bipolar Disorder; Brain; Case-Control Studies; Executive Function; Female | 2018 |
Practical guidance for using multiple data sources in systematic reviews and meta-analyses (with examples from the MUDS study).
Topics: Amines; Bipolar Disorder; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Data Collection; Ga | 2018 |
GAD1 gene polymorphisms are associated with bipolar I disorder and with blood homovanillic acid levels but not with plasma GABA levels.
Topics: Adult; Biomarkers; Bipolar Disorder; Female; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Haplo | 2019 |
Lithium and GADL1 regulate glycogen synthase kinase-3 activity to modulate KCTD12 expression.
Topics: Asian People; Bipolar Disorder; Carboxy-Lyases; Case-Control Studies; Cell Line, Tumor; gamma-Aminob | 2019 |
Manic symptoms associated with pregabalin in a patient with conversion disorder.
Topics: Anticonvulsants; Bipolar Disorder; Conversion Disorder; gamma-Aminobutyric Acid; Humans; Male; Middl | 2013 |
Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder.
Topics: Adult; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Female; gamma-Aminob | 2013 |
Reversal of aripiprazole-induced tardive akathisia by addition of pregabalin.
Topics: Adult; Akathisia, Drug-Induced; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Bipolar Disorde | 2013 |
Cortical glutathione levels in young people with bipolar disorder: a pilot study using magnetic resonance spectroscopy.
Topics: Aspartic Acid; Biomarkers; Bipolar Disorder; Case-Control Studies; Female; Functional Neuroimaging; | 2014 |
Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid.
Topics: Adult; Age Factors; Anxiety; Bipolar Disorder; Case-Control Studies; Chromatography, High Pressure L | 2014 |
DNA-methyltransferase1 (DNMT1) binding to CpG rich GABAergic and BDNF promoters is increased in the brain of schizophrenia and bipolar disorder patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Bipolar Disorder; Brain; Brain-Derived Neurotrophic F | 2015 |
Proteomic pathway analysis of the hippocampus in schizophrenia and bipolar affective disorder implicates 14-3-3 signaling, aryl hydrocarbon receptor signaling, and glucose metabolism: potential roles in GABAergic interneuron pathology.
Topics: 14-3-3 Proteins; Adult; Bipolar Disorder; Female; gamma-Aminobutyric Acid; Glucose; Hippocampus; Hum | 2015 |
Circuit- and Diagnosis-Specific DNA Methylation Changes at γ-Aminobutyric Acid-Related Genes in Postmortem Human Hippocampus in Schizophrenia and Bipolar Disorder.
Topics: Adaptor Proteins, Signal Transducing; Bipolar Disorder; Case-Control Studies; Co-Repressor Proteins; | 2015 |
Altered Markers of Cortical γ-Aminobutyric Acid Neuronal Activity in Schizophrenia: Role of the NARP Gene.
Topics: Biomarkers; Bipolar Disorder; C-Reactive Protein; Case-Control Studies; Cytoskeletal Proteins; Depre | 2015 |
Vitamin D3 Supplemental Treatment for Mania in Youth with Bipolar Spectrum Disorders.
Topics: Adolescent; Affect; Bipolar Disorder; Child; Cholecalciferol; Dietary Supplements; Female; gamma-Ami | 2015 |
Anterior cingulate Glutamate-Glutamine cycle metabolites are altered in euthymic bipolar I disorder.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents; Bipolar Disorder; Female; gamma-Amin | 2015 |
Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol.
Topics: Amines; Analgesics; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Data Interp | 2015 |
A sensitive and practical RP-HPLC-FLD for determination of the low neuroactive amino acid levels in body fluids and its application in depression.
Topics: Aged; Aged, 80 and over; Amino Acids; Bipolar Disorder; Body Fluids; Case-Control Studies; Chromatog | 2016 |
Trait- and state-dependent cortical inhibitory deficits in bipolar disorder.
Topics: Adult; Bipolar Disorder; Cerebral Cortex; Character; Corpus Callosum; Female; gamma-Aminobutyric Aci | 2016 |
Cortical GABA markers identify a molecular subtype of psychotic and bipolar disorders.
Topics: Adult; Biomarkers; Bipolar Disorder; Female; GABAergic Neurons; gamma-Aminobutyric Acid; Glutamate D | 2016 |
Perisylvian GABA levels in schizophrenia and bipolar disorder.
Topics: Adult; Antipsychotic Agents; Auditory Cortex; Bipolar Disorder; Female; gamma-Aminobutyric Acid; Hum | 2017 |
Patterns of prescribing antiepileptic drugs for bipolar disorder.
Topics: Adult; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Drug-Related Side Eff | 2008 |
Disseminating findings from a drug class review: using best practices to inform prescription of antiepileptic drugs for bipolar disorder.
Topics: Advertising; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Evidence-Based | 2008 |
Circuitry-based gene expression profiles in GABA cells of the trisynaptic pathway in schizophrenics versus bipolars.
Topics: Bipolar Disorder; Female; gamma-Aminobutyric Acid; Gene Expression Profiling; Gene Expression Regula | 2008 |
Neurochemical alterations in adolescent bipolar depression: a proton magnetic resonance spectroscopy pilot study of the prefrontal cortex.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Aspartic Acid; Bipolar Dis | 2008 |
Brain GABA levels in patients with bipolar disorder.
Topics: Adult; Bipolar Disorder; Brain; Brain Mapping; Case-Control Studies; Female; gamma-Aminobutyric Acid | 2009 |
Site-specific regulation of cell cycle and DNA repair in post-mitotic GABA cells in schizophrenic versus bipolars.
Topics: Bipolar Disorder; Cell Cycle; DNA Repair; Endodeoxyribonucleases; gamma-Aminobutyric Acid; Gene Expr | 2009 |
GABA and homovanillic acid in the plasma of Schizophrenic and bipolar I patients.
Topics: Adolescent; Adult; Biomarkers; Bipolar Disorder; Dopamine; Female; gamma-Aminobutyric Acid; Homovani | 2010 |
Outcome reporting in industry-sponsored trials of gabapentin for off-label use.
Topics: Amines; Bipolar Disorder; Clinical Protocols; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobu | 2009 |
Relationship of GAD(67) regulation to cell cycle and DNA repair in GABA neurons in the adult hippocampus: bipolar disorder versus schizophrenia.
Topics: Bipolar Disorder; Cell Cycle; DNA Repair; gamma-Aminobutyric Acid; Gene Expression Regulation; Gluta | 2010 |
The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion.
Topics: Adolescent; Adult; Amines; Anti-Anxiety Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Evide | 2010 |
Expression of the Rap1 guanine nucleotide exchange factor, MR-GEF, is altered in individuals with bipolar disorder.
Topics: Animals; Bipolar Disorder; Case-Control Studies; Down-Regulation; gamma-Aminobutyric Acid; Guanine N | 2010 |
Editorial: Etiological hypotheses of mental disorders at the molecular level.
Topics: Bipolar Disorder; Circadian Rhythm; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Mental Disorders | 2010 |
GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders.
Topics: Adult; Age Factors; Aged; Biomarkers; Bipolar Disorder; Down-Regulation; Female; gamma-Aminobutyric | 2011 |
Off-label prescribing explained. Why your doctor may recommend meds that aren't FDA-approved for your condition.
Topics: Amines; Bipolar Disorder; Clinical Protocols; Cyclohexanecarboxylic Acids; Drug Approval; Drug Label | 2011 |
Differences in the circuitry-based association of copy numbers and gene expression between the hippocampi of patients with schizophrenia and the hippocampi of patients with bipolar disorder.
Topics: Bipolar Disorder; gamma-Aminobutyric Acid; Gene Dosage; Gene Expression Regulation; Glutamate Decarb | 2012 |
Gene expression of GABA and glutamate pathway markers in the prefrontal cortex of non-suicidal elderly depressed patients.
Topics: Aged; Aged, 80 and over; Bipolar Disorder; Depressive Disorder, Major; Female; gamma-Aminobutyric Ac | 2012 |
Pregabalin in the treatment of refractory bipolar disorders.
Topics: Bipolar Disorder; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Pregabalin; Substance-Related | 2012 |
Platelet uptake of GABA and glutamate in patients with bipolar disorder.
Topics: Adult; Aged; Analysis of Variance; Bipolar Disorder; Female; gamma-Aminobutyric Acid; Glutamic Acid; | 2012 |
Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation.
Topics: Access to Information; Amines; Analgesics; Antimanic Agents; Authorship; Bipolar Disorder; Clinical | 2012 |
An open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment resistant bipolar disorder.
Topics: Adolescent; Adult; Affect; Aged; Aged, 80 and over; Antimanic Agents; Bipolar Disorder; Female; gamm | 2013 |
Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
Topics: Amines; Anticonvulsants; Bipolar Disorder; Compensation and Redress; Cyclohexanecarboxylic Acids; Dr | 2012 |
Reduced GAD(65/67) immunoreactivity in the hypothalamic paraventricular nucleus in depression: a postmortem study.
Topics: Adult; Aged; Aged, 80 and over; Autopsy; Bipolar Disorder; Corticotropin-Releasing Hormone; Depressi | 2013 |
Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons.
Topics: Bipolar Disorder; Calbindin 2; Calbindins; Cerebral Cortex; Depression; gamma-Aminobutyric Acid; Hum | 2002 |
Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity?
Topics: Acetates; Adult; Aged; Alcoholism; Amines; Anticonvulsants; Antimanic Agents; Anxiety Disorders; Bip | 2002 |
Some possible genetic parallels across alcoholism, bipolar disorder and schizophrenia.
Topics: Alcoholism; Bipolar Disorder; Catecholamines; Chromosome Deletion; Chromosomes, Human, Pair 10; Chro | 2003 |
Gabapentin in geriatric mania.
Topics: Acetates; Aged; Aged, 80 and over; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cycl | 2003 |
Brain metabolic alterations in medication-free patients with bipolar disorder.
Topics: Adult; Ambulatory Care; Bipolar Disorder; Brain; Brain Chemistry; Creatine; Echo-Planar Imaging; Fem | 2004 |
Neural synchronization deficits to auditory stimulation in bipolar disorder.
Topics: Acoustic Stimulation; Adult; Auditory Perceptual Disorders; Bipolar Disorder; Cerebral Cortex; Cogni | 2004 |
Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder.
Topics: Adult; Aged; Bipolar Disorder; Cell Count; Digoxigenin; Female; gamma-Aminobutyric Acid; Gene Expres | 2004 |
Immunohistochemical and immunoblot study of GABA(A) alpha1 and beta2/3 subunits in the prefrontal cortex of subjects with schizophrenia and bipolar disorder.
Topics: Adult; Aged; Aged, 80 and over; Bipolar Disorder; Female; gamma-Aminobutyric Acid; Humans; Image Cyt | 2004 |
Interferon for hepatitis C patients with psychiatric disorders.
Topics: Amines; Antimanic Agents; Antiviral Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Drug Ther | 2004 |
Hippocampus, III: GABA-containing cell bodies and GAD mRNA.
Topics: Bipolar Disorder; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Hippocampus; Humans; Pyramidal C | 2005 |
Gabapentin withdrawal syndrome in the presence of a taper.
Topics: Aged; Aged, 80 and over; Amines; Antimanic Agents; Bipolar Disorder; Chest Pain; Cyclohexanecarboxyl | 2005 |
Changes in hippocampal GABAA receptor subunit composition in bipolar 1 disorder.
Topics: Adult; Aged; Binding, Competitive; Bipolar Disorder; Brain Chemistry; Clonazepam; Female; Flumazenil | 2005 |
Atypical antipsychotics in bipolar depression: potential mechanisms of action.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Dopamine; gamma-Aminobu | 2005 |
Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression.
Topics: Bipolar Disorder; Cerebral Cortex; Depressive Disorder, Major; Excitatory Amino Acid Transporter 1; | 2005 |
Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects.
Topics: Adult; Aged; Analysis of Variance; Aspartic Acid; Bipolar Disorder; Brain Mapping; Depressive Disord | 2007 |
Gabapentin-related changes in renal function: two case reports.
Topics: Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Diabetes Insipidus, Nephrog | 2007 |
Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder.
Topics: Adult; Aged; Aged, 80 and over; Basal Ganglia; Bipolar Disorder; Caudate Nucleus; Cell Adhesion Mole | 2007 |
Dysregulation of GABAergic neurotransmission in mood disorders: a postmortem study.
Topics: Aged; Bipolar Disorder; Brain; Brain Mapping; Female; gamma-Aminobutyric Acid; Gene Expression Regul | 2007 |
DNA fragmentation is increased in non-GABAergic neurons in bipolar disorder but not in schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Bipolar Disorder; Cell Count; Cohort Studies; DNA Fragmen | 2007 |
Chronic lamotrigine does not alter the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat: implications for the treatment of bipolar disorder.
Topics: Acyl Coenzyme A; Animals; Antimanic Agents; Arachidonic Acid; Bipolar Disorder; Brain; Disease Model | 2007 |
Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars.
Topics: Bipolar Disorder; Case-Control Studies; Down-Regulation; Female; gamma-Aminobutyric Acid; Gene Expre | 2007 |
Divalproex, lithium and suicide among Medicaid patients with bipolar disorder.
Topics: Adult; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Emerge | 2008 |
Changes in density of calcium-binding-protein-immunoreactive GABAergic neurons in prefrontal cortex in schizophrenia and bipolar disorder.
Topics: Bipolar Disorder; Calcium-Binding Proteins; Female; gamma-Aminobutyric Acid; Humans; Image Processin | 2008 |
Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder.
Topics: Adult; Analysis of Variance; Animals; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Case-Contro | 2009 |
CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls.
Topics: Adolescent; Adult; Age Factors; Aged; Bipolar Disorder; Calcium; Choline; Depressive Disorder; Femal | 1984 |
Plasma GABA levels in psychiatric illness.
Topics: Alcoholism; Bipolar Disorder; Depressive Disorder; Dexamethasone; gamma-Aminobutyric Acid; Humans; L | 1984 |
A second generation catecholamine hypothesis.
Topics: Animals; Bipolar Disorder; Brain; Catecholamines; Dopamine; gamma-Aminobutyric Acid; Humans; Lithium | 1982 |
Pharmacological and therapeutic actions of GABA receptor agonists.
Topics: Bipolar Disorder; Emotions; gamma-Aminobutyric Acid; Humans; Movement Disorders; Norepinephrine; Rec | 1983 |
Reduced plasma and CSF gamma-aminobutyric acid in affective illness: effect of lithium carbonate.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Female; gamma-Aminobutyric Acid; Humans; Lithium; Lith | 1983 |
Plasma GABA in affective illness. A preliminary investigation.
Topics: Bipolar Disorder; Depressive Disorder; Female; gamma-Aminobutyric Acid; Humans; Male; Schizophrenia | 1981 |
On a possible role of GABA in mania. Therapeutic efficacy of sodium valproate.
Topics: Affective Disorders, Psychotic; Bipolar Disorder; Double-Blind Method; Drug Evaluation; gamma-Aminob | 1981 |
Platelet GABA-transaminase in affective illness.
Topics: 4-Aminobutyrate Transaminase; Adult; Bipolar Disorder; Blood Platelets; Diseases in Twins; Female; g | 1982 |
Possible drug differentiation of the psychoses.
Topics: Affective Disorders, Psychotic; Bipolar Disorder; Diagnosis, Differential; gamma-Aminobutyric Acid; | 1982 |
Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders.
Topics: Adult; Age Factors; Bipolar Disorder; Depressive Disorder; Female; gamma-Aminobutyric Acid; Homovani | 1982 |
State-related cyclical dyskinesias in manic-depressive illness.
Topics: Adult; Bipolar Disorder; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Humans; Male; Mi | 1982 |
Plasma and CSF GABA in affective illness.
Topics: Adult; Bipolar Disorder; Diseases in Twins; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Ag | 1982 |
Lack of effect of carbamazepine on gamma-aminobutyric acid in cerebrospinal fluid.
Topics: Adult; Bipolar Disorder; Carbamazepine; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged | 1980 |
CSF GABA in normal subjects and patients with depression, schizophrenia, mania, and anorexia nervosa.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Aged; Anorexia Nervosa; Bipolar Disorder; Depress | 1981 |
GABA levels in CSF of patients with psychiatric disorders.
Topics: Adult; Aged; Bipolar Disorder; Depression; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Age | 1980 |
Hypomania induced by gabapentin.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Dose-Response Rela | 1995 |
Low plasma GABA is a trait-like marker for bipolar illness.
Topics: Adult; Biomarkers; Bipolar Disorder; Chromatography, High Pressure Liquid; gamma-Aminobutyric Acid; | 1993 |
Hypomania induced by gabapentin.
Topics: Acetates; Affect; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Electroenc | 1995 |
A linkage study between bipolar disorder and genes involved in dopaminergic and GABAergic neurotransmission.
Topics: Bipolar Disorder; Carrier Proteins; Dopamine; Dopamine beta-Hydroxylase; Dopamine Plasma Membrane Tr | 1996 |
Treatment of acute mania with gabapentin.
Topics: Acetates; Acute Disease; Adult; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Aci | 1997 |
Gabapentin in bipolar disorder.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic | 1997 |
Acute treatment of bipolar depression with gabapentin.
Topics: Acetates; Acute Disease; Adult; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Aci | 1997 |
Gabapentin in geriatric psychiatry patients.
Topics: Acetates; Aged; Aged, 80 and over; Alzheimer Disease; Amines; Anticonvulsants; Bipolar Disorder; Cyc | 1998 |
Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania.
Topics: Acetates; Adult; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Dose-Respon | 1998 |
Gabapentin in the treatment of adolescent mania: a case report.
Topics: Acetates; Adolescent; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cyclohexanecarbox | 1998 |
Advances in mood stabilizing medications.
Topics: Acetates; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Calcium Channel Blockers; Cyc | 1998 |
Gabapentin treatment of mood disorders: a preliminary study.
Topics: Acetates; Adolescent; Adult; Aged; Ambulatory Care; Amines; Anticonvulsants; Antidepressive Agents; | 1998 |
Renal impairment as a possible side effect of gabapentin. A single case report.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Drug Thera | 1998 |
GABAA alpha-1 subunit gene not associated with depressive symptomatology in mood disorders.
Topics: Adult; Anxiety; Bipolar Disorder; Delusions; Depression; DNA; Female; gamma-Aminobutyric Acid; Genet | 1998 |
Possible gabapentin-induced thyroiditis.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxyl | 1999 |
Gabapentin as monotherapy in the treatment of acute mania.
Topics: Acetates; Acute Disease; Adult; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Aci | 1999 |
Catatonia following gabapentin withdrawal.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Female; Gabapentin | 1999 |
Gabapentin-induced ejaculatory failure and anorgasmia.
Topics: Acetates; Adult; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Ejaculation | 1999 |
Mood stabilizer combinations for bipolar disorder.
Topics: Acetates; Adolescent; Age Factors; Amines; Antimanic Agents; Bipolar Disorder; Child; Cyclohexanecar | 1999 |
Gabapentin as a promising treatment for antipsychotic-induced movement disorders in schizoaffective and bipolar patients.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecar | 1999 |
Gabapentin as an adjunctive treatment in bipolar disorder.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Drug Thera | 1999 |
Antidepressant-induced bruxism successfully treated with gabapentin.
Topics: Acetates; Amines; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Bipolar Disorder; B | 1999 |
Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment.
Topics: Acetates; Acute Disease; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Ac | 1999 |
Manic episode due to gabapentin treatment.
Topics: Acetates; Adult; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Female; Gab | 1999 |
Anorgasmia in a patient with bipolar disorder type 1 treated with gabapentin.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapentin | 2000 |
Gabapentin for treatment of bipolar and schizoaffective disorders.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Female; Ga | 1997 |
Valproate and other anticonvulsants for psychiatric disorders.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Bipolar | 2000 |
Evaluating the tolerability of the newer mood stabilizers.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Central Nervous System Diseases; Cyclohexanecar | 2001 |
Glutamate decarboxylase(65)-immunoreactive terminals in cingulate and prefrontal cortices of schizophrenic and bipolar brain.
Topics: Adult; Aged; Antibodies; Bipolar Disorder; Female; gamma-Aminobutyric Acid; Glutamate Decarboxylase; | 2000 |
Gabapentin-induced anorgasmia as a cause of noncompliance in a bipolar patient.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapentin | 2001 |
Adjunctive gabapentin in patients with intellectual disability and bipolar spectrum disorders.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Comorbidity; Cyclohexanecarboxylic Acid | 2001 |
Gabapentin treatment of the non-refractory bipolar spectrum: an open case series.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Depressive | 2001 |
Gabapentin as prophylaxis against steroid-induced mania.
Topics: Acetates; Amines; Anti-Inflammatory Agents; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxyli | 2001 |
Gabapentin-associated aggression.
Topics: Acetates; Adult; Aggression; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids | 2001 |
Quetiapine-related tardive dyskinesia.
Topics: Acetates; Adult; Amines; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecarboxy | 2001 |
Gabapentin and methylphenidate treatment of a preadolescent with attention deficit hyperactivity disorder and bipolar disorder.
Topics: Acetates; Amines; Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; | 2001 |
Gabapentin use in geriatric patients with depression and bipolar illness.
Topics: Acetates; Aged; Aged, 80 and over; Amines; Antidepressive Agents; Bipolar Disorder; Cyclohexanecarbo | 2001 |
GluR5,6,7 subunit immunoreactivity on apical pyramidal cell dendrites in hippocampus of schizophrenics and manic depressives.
Topics: Adult; Aged; Aged, 80 and over; Bipolar Disorder; Dendrites; gamma-Aminobutyric Acid; GluK2 Kainate | 2001 |
The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia.
Topics: Adult; Bipolar Disorder; Calcium-Binding Proteins; Cell Count; Depressive Disorder, Major; Female; g | 2002 |
Gabapentin treatment of impulsive-aggressive behaviour.
Topics: Acetates; Adult; Aggression; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids | 2002 |
Mass spectrometric identification and selected ion monitoring quantitation of gamma-amino-butyric acid (GABA) in human lumbar cerebrospinal fluid.
Topics: Bipolar Disorder; Chromatography, Gas; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Hu | 1978 |
[Certain principles for differential utilization of metabolic treatment preparations in the complex therapy of mental disorders].
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Brain Injuries; gamma-Aminobutyric Acid; Humans; Infectio | 1979 |
CSF GABA in depressed patients and normal controls.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Female; gamma-Aminobutyric Acid; Homovanillic Acid; Hu | 1991 |
Lithium mechanisms in bipolar illness and altered intracellular calcium functions.
Topics: Adenylyl Cyclases; Bipolar Disorder; Calcium; Calcium-Transporting ATPases; Enzyme Activation; gamma | 1986 |
Cerebrospinal fluid studies of bipolar patients with and without a history of suicide attempts.
Topics: Bipolar Disorder; gamma-Aminobutyric Acid; Humans; Neuropeptides; Neurotransmitter Agents; Suicide, | 1986 |
[GABA receptor function and manic depressive disease].
Topics: Anticonvulsants; Bipolar Disorder; gamma-Aminobutyric Acid; Humans; Receptors, GABA-A | 1986 |
GABA and circadian timekeeping: implications for manic-depression and sleep disorders.
Topics: 4-Aminobutyrate Transaminase; Acetylcholine; Aldehyde Oxidoreductases; Animals; Benzodiazepines; Bip | 1986 |
Is there a common denominator for the antimanic effect of lithium and anticonvulsants?
Topics: Acetylcholine; Anticonvulsants; Bipolar Disorder; Brain; Dopamine; gamma-Aminobutyric Acid; Humans; | 1987 |
CSF GABA in euthymic manic-depressive patients and controls.
Topics: Adult; Bipolar Disorder; Female; gamma-Aminobutyric Acid; Humans; Lithium | 1986 |